



King's Research Portal

DOI:

[10.1159/000497035](https://doi.org/10.1159/000497035)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Rasika, S., Passemard, S., Verloes, A., Gressens, P., & El Ghouzzi, V. (2019). Golgipathies in Neurodevelopment: A New View of Old Defects. *Developmental Neuroscience*, 40(5-6), 396-416. <https://doi.org/10.1159/000497035>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

1
2 **Golgipathies in Neurodevelopment:**
3 **A New View of Old Defects**
4
5

6 Sowmyalakshmi Rasika^{1,2}, Sandrine Passemard^{1,2}, Alain Verloes^{1,2}, Pierre
7 Gressens^{1,3}, Vincent El Ghouzzi^{1*}
8

9 1. PROTECT, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France

10 2. AP HP, Hôpital Robert Debré, UF de Génétique Clinique, Paris, France

11 3. Centre for the Developing Brain, Division of Imaging Sciences and Biomedical
12 Engineering, King's College London, King's Health Partners, St. Thomas' Hospital,
13 London, United Kingdom
14

15 ***Corresponding author:**

16 Vincent El Ghouzzi

17 Address: Inserm U1141, Hôpital Robert-Debré, 48 Boulevard Sérurier, F-75019,
18 Paris, France.

19 E-mail: vincent.elghouzzi@inserm.fr

20 Phone: +331 40031973, Fax: +331 40031995
21

22 **Running Head:** Golgipathies and Neurodevelopment

23 **Key words:** Golgi apparatus; microcephaly; intellectual disability; neurodevelopment;
24 trafficking; cell cycle; apoptosis

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Abstract

The Golgi Apparatus (GA) is involved in a whole spectrum of activities, from lipid biosynthesis and membrane secretion to the post-translational processing and trafficking of most proteins, to the control of mitosis, cell polarity, migration and morphogenesis, to diverse processes such as apoptosis, autophagy and the stress response. In keeping with its versatility, mutations in GA proteins lead to a number of different disorders, including syndromes with multi-system involvement. Intriguingly, however, over 40% of the GA-related genes known to be associated with disease affect the central or peripheral nervous system, highlighting the critical importance of the GA to neural function. We have previously proposed the term "Golgipathies" in relation to a group of disorders in which mutations in GA proteins or their molecular partners lead to consequences in terms of brain development, in particular postnatal-onset microcephaly (POM), white matter defects and intellectual disability (ID). Here, taking into account the broader role of the GA in the nervous system, we refine and enlarge this emerging concept to include other disorders whose symptoms may be indicative of altered neurodevelopmental processes, from neurogenesis to neuronal migration, to the secretory function critical for the maturation of postmitotic neurons and myelination.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Introduction

One hundred and twenty years ago, in 1898, Camillo Golgi first published his observations of an "internal reticular complex" that surrounded the nucleus of Purkinje cells in the barn owl cerebellum, using his now eponymous silver reduction method [1]. Despite Golgi's demonstration of his reticular complex in a variety of mammalian cell types in addition to neurons, the very existence of this complex, which we now call the Golgi complex or Golgi apparatus (GA), as an independent and consistent intracellular entity was in doubt for much of the first half of its history, in large part because of its variable morphology and technological and methodological limitations. Also in doubt was what specific role, if any, this strange structure could possibly play. We have known for a few decades now that the GA not only exists but is ubiquitous in all eukaryotic cells, from the yeast upward. However, our views on what it does and how it does it continue to evolve.

The best known and most widely accepted roles of the GA are of course in the biosynthesis of some lipids such as glycolipids and sphingomyelin, and in the processing, sorting, packing, routing and recycling of secretory cargo downstream of the endoplasmic reticulum (ER), roles that are important for cellular and organ function throughout the lifespan. However, the GA plays a number of other roles, many of which are of particular importance during development – it participates in cell division, migration, morphogenesis and growth (all of which involve diverse aspects including intracellular organization, polarity and compartmentalization), as well as apoptosis, autophagy and the stress response. In keeping with these multiple roles, many "GA proteins" are also present in other intracellular compartments and are involved in more than one function, including acting as signaling molecules, rather than acting at a purely structural/mechanical or enzymatic level.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

The ubiquitous nature of the GA means that any pathogenic mutation perturbing the function of a GA protein could and mostly does result in clinical repercussions across multiple tissues and systems. Strikingly, of the mutated GA-associated genes identified in various monogenic disorders so far, over 40% affect the normal development or functioning of the central or peripheral nervous system, a far greater proportion than for any other tissue type [2], highlighting its crucial roles in different types of neural cells. Indeed, the magnitude of this impact on the nervous system structure and physiology and on neurodevelopment in particular should not be surprising, when one considers the intensive use that neurons and glia presumably make of the GA – in the intricately coordinated processes involved in progenitor cell organization, orientation and mitosis; the subsequent highly directional migration of young neurons to their target regions; the exponential increase in surface area and thus of the biosynthesis of both membrane lipids and proteins required by diverse processes such as dendritic arborization in neurons and myelin sheath production in oligodendrocytes; the heavy demands of synaptogenesis and synaptic and neurosecretory activity, etc. The existence of Golgi outposts in dendrites is a prime example of the adaptation of the GA to the highly compartmentalized nature of the nervous system and its specific trafficking needs (reviewed in [3,4]).

19
20
21
22
23
24
25

Intriguingly, during the course of our identification of the causal gene and molecular mechanisms underlying Dyggve-Melchior-Clausen (DMC, MIM #223800) syndrome, a disorder in which skeletal defects are associated with a characteristic neurological profile combining postnatal-onset microcephaly (POM), white matter deficits and intellectual disability (ID) [5], we noted the presence of the same combination of symptoms in several other monogenic disorders, each of which was linked to a defect in a gene involved in the GA trafficking machinery. This common profile indicated a similar pathophysiology – defective

1 neuronal or oligodendrocytic maturation at the post-mitotic stage, thus leading to symptoms
2 later during neurodevelopment than in the primary or congenital microcephalies, which result
3 principally from proliferation deficits. Additionally, several of these newly or previously
4 identified disorders appeared to involve a mutation in a GA-associated member of the small
5 RAB GTPase family, which are involved in a plethora of trafficking functions in the cell, or in
6 molecules that interact with the RABs, including their direct effectors and modulators such as
7 the guanine nucleotide exchange factors – GEFs – which activate them by replacing GDP by
8 GTP and allowing them to bind specific effectors, or the GTPase activating proteins – GAPs,
9 which dissociate the active complex. These observations prompted us to propose the term
10 "Golgipathies" or "Golgipathic microcephalies" to designate this emerging class of disorders
11 characterized by a similar phenotype (POM, white matter deficits, notably an abnormal corpus
12 callosum, and varying degrees of cognitive impairment), and caused by mutations in RAB
13 GTPases or their molecular partners [4]. However, an examination of the literature and recently
14 published studies provides ample evidence that defective GA proteins and processes are linked
15 to a wide spectrum of neurodevelopmental defects in addition to the combination that first drew
16 our attention. Not only are there a large number of isolated reports of POM related to GA- or
17 RAB-associated mutations, but a number of other disorders, including several characterized by
18 congenital microcephaly, could also justifiably be classified as Golgipathies, based on the fact
19 that the primary pathogenic mechanism in all of them is a defective GA protein, regardless of
20 its intracellular function (GA structure or intracellular organization, trafficking machinery in
21 the anterograde or retrograde directions, post-translational modifications, cell-cycle
22 involvement...). In light of these new insights, we would like to refine the notion of
23 Golgipathies, taking into account their major neurodevelopmental involvement, with a brief
24 discussion of the relationship between these disorders and the possible GA functions affected.

25

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Golgipathies: more microcephalies and more than microcephalies

Despite their great variety, Golgipathies with a neurodevelopmental component also show considerable overlap and a number of unifying features. Some of these putative neurodevelopmental Golgipathies are described below, grouped according to their principal clinical signs (presence or absence of microcephaly and its onset), and the probable function or position in the trafficking pathway of the affected protein, in order to stimulate discussion as to their potential classification. We have excluded cancer-related GA genes/proteins or those involved in primarily neurodegenerative processes.

I. POM Golgipathies related to RAB GTPases and their molecular partners:

Perhaps due to the fact that most important and "permanent" functions of the GA is that of lipid and protein trafficking, crucial throughout the lifespan of the cell, the POMs constitute a disproportionately large group of Golgipathies affecting neurodevelopment. While many involve other organs and tissues and show remarkable differences in phenotype between one individual and the next, for the purposes of this review, we will concentrate on the neurological aspects (summarized in **Table 1**).

Dyggve-Melchior-Clausen syndrome (DMC; MIM #223800), which first prompted our speculation about Golgipathies as a class of disorders, is an autosomal recessive skeletal dysplasia associated with POM and ID, and caused by loss-of-function mutations in the *DYM* gene encoding DYMECLIN, a GA protein involved in intracellular trafficking [6-8]. Brain MRI reveals a marked thinning of the corpus callosum and brain stem, supported by significant deficits in the volume and structure of myelin in *Dym*^{-/-} mutant mice [5] *Dym*-deficient neurons display a fragmented GA and impaired ER-to-GA trafficking [5], but *Dym* may also

1 play a role in the retrograde transport of vesicles from the GA to the ER [7]. Several lines of
2 evidence suggest that it has a tethering role during vesicle trafficking between the ER and the
3 GA [6,7] in conjunction with the golgin GIANTIN and interactions with RAB1 or RAB6, the
4 most abundant type of RAB [9-11]. Interestingly, *Smith McCort dysplasia*, a clinical variant of
5 DMC syndrome with identical skeletal defects but normal intelligence and no microcephaly,
6 has been found to result either from specific missense mutations in *DYM* that could result in
7 some residual activity of the protein (SMC1; MIM #607326) [6,12] or from loss-of-function
8 mutations in the RAB33B GTPase, also localized in the GA (SMC2; MIM #615222) [13,14].

9 *Warburg-Micro syndrome* (WARBM1-4; MIM #600118, #614225, #614222, #615663)
10 is an autosomal recessive disorder [15] characterized by neurodevelopmental defects including
11 POM with profound ID, and progressive limb spasticity associated with progressive peripheral
12 axonal neuropathy [16], severe visual impairment and hypogonadism. Brain MRI shows
13 bilateral frontal polymicrogyria and hypoplasia of the corpus callosum and cerebellar vermis
14 [17,18]. Loss-of-function mutations in four distinct genes, *RAB3GAP1*, *RAB3GAP2*, *RAB18*
15 and *TBC1D20*, have been implicated in WARBM [18-20]. RAB18 has recently been confirmed
16 to localize in the ER and the *cis*-Golgi compartment [21], in addition to other compartments.
17 While TBC1D20 acts as a GAP for RAB18, in addition to acting on ER-localized RAB1 [22]
18 the RAB3GAP complex in this context acts not as a GAP but as a GEF for RAB18 [23]. In the
19 related *Martsolf syndrome* (MIM #212720), only *RAB3GAP2* mutations have been identified,
20 but most patients also display severe neurodevelopmental defects including POM and white
21 matter defects (where examined), ID, hypogonadism and ocular defects [19,24,25].

22 Mutations in *COL4A3BP* (collagen 4A3 binding protein, also known as Goodpasture
23 antigen binding protein, GPBP, or ceramide transporter, CERT) lead to an *autosomal dominant*
24 *mental retardation* (MRD34; MIM #616351). The COL4A3BP protein is thought to mediate
25 ER-to-GA transport of ceramide, an essential lipid component. One of the first patients

1 identified with a mutation in this gene presented with POM in addition to other neurological
2 and skeletal defects [26].

3 Autosomal recessive mental retardation 13 (MRT13; MIM #613192) is linked to loss-
4 of-function mutations in *TRAPPC9*. Initially considered a nonsyndromic autosomal recessive
5 ID [27-29], with additional cases, MRT13 is beginning to show a fairly distinctive phenotype,
6 including moderate to severe POM, a peculiar facial appearance, obesity and hypotonia. MRI
7 reveals a reduction in cerebral white matter with a marked thinning of the corpus callosum [30-
8 32]. *TRAPPC9* is a subunit of the Trafficking Protein Particle (TRAPP) complex that mediates
9 the tethering of COPII-coated ER-derived vesicles to *cis*-Golgi membranes [33]. The TRAPP
10 complex acts by activating RAB1, which in turn recruits specific *cis*-Golgi effectors such as the
11 golgins P115 and GM130 to allow vesicle tethering [34]. The TRAPP complex and *TRAPPC9*
12 in particular are also involved in the interaction between COPII-coated vesicles and the
13 microtubule motor protein dynactin 1 (*DCTN1*, equivalent to the *Drosophila* p150^{Glued}) [35].

14 Progressive childhood encephalopathy (PEBAS; MIM #617669), also linked to
15 mutations in a TRAPP subunit, *TRAPPC12*, has been identified in 2 families as being linked to
16 progressive microcephaly (including one case of POM), agenesis of the corpus callosum and
17 other MRI abnormalities, and severe developmental delays [36]. Mutations in another TRAPP
18 subunit, *TRAPPC6B*, have also been linked to a POM syndrome (NEDMEBA; MIM #617862)
19 in several families in a recent report [37].

20 In Takenouchi-Kosaki syndrome (TKS; MIM #616737), caused by mutations in the GA
21 GTPase *CDC42*, which regulates bidirectional Golgi transport by regulating the cargo sorting
22 and carrier formation functions of COPI [38], affected patients show a range of phenotypes
23 affecting different organs, including ID and either POM or congenital microcephaly (reviewed
24 in [39]).

1 *A neuromuscular syndrome with microcephaly* noticeable from the 4th postnatal month
2 has been described in an individual who also displayed developmental delays, seizures,
3 hypotonia and muscular dystrophy [40]. Brain MRI revealed delayed myelination and a
4 thinning of the corpus callosum. The molecular cause was a loss of function of the *GOLGA2*
5 gene (MIM #602582), which encodes GM130, a multifunctional golgin involved in both the
6 assembly/maintenance of GA structure and the regulation of the secretory pathway and vesicle
7 tethering to the *cis*-Golgi compartment through interactions with RAB1B, P115 etc.; GM130
8 also binds to other RAB proteins involved in membrane traffic regulation at the ER/Golgi
9 interface, such as RAB2 and RAB33B [41-43].

10 *Autosomal recessive mental retardation 61* (MRT61; MIM #617773), also called
11 Alwadei syndrome, is a POM syndrome that includes profound ID, epilepsy in two cases and a
12 thin corpus callosum [44]; it has been found to be caused by mutations in IPORIN (MIM
13 #617773), a protein encoded by the *RUSC2* gene. Little is known about the RUSC2 protein
14 except that it is ubiquitous and highly expressed in the brain, and interacts with both RAB1B
15 and possibly directly with GM130 [45].

16 *Cohen syndrome* (COH; #MIM 216550) is an autosomal recessive disorder
17 characterized by motor delays, progressive retinal dystrophy and severe myopia, hypotonia,
18 joint hypermobility and progressive POM associated with ID [46], associated at times with
19 non-neurological signs [47]. Brain MRI reveals a relatively thicker but more compact corpus
20 callosum in some patients, associated with markedly smaller sagittal diameters of the brain
21 stem [48]. *COH1*, the only gene associated with Cohen syndrome so far, encodes the vacuolar
22 protein-sorting protein VPS13B, a large peripheral membrane protein that is actively recruited
23 at the GA by RAB6 [49,50]. VPS13B likely plays a specific role in the dynamics and function
24 of the GA, in particular during neuronal maturation.

1 Progressive Cerebello-Cerebral Atrophy type 2 or Ponto-Cerebellar Hypoplasia type
 2 2E (PCCA2/PCH2E; MIM #615851) is an autosomal recessive neurodegenerative disorder
 3 characterized by normal development during the initial months of life, followed by motor
 4 delays, progressive POM, progressive spasticity and epileptic seizures by two years of age [51].
 5 Brain MRI reveals a gradual decrease in cerebral white matter associated with delayed
 6 myelination and thinning of the corpus callosum [51]. The responsible gene encodes VPS53,
 7 another vacuolar protein-sorting protein that participates in the transport and recycling of
 8 endosome-derived transport vesicles [52]. VPS53 is part of two large multisubunit complexes
 9 named Golgi-associated retrograde protein (GARP) and Endosome-associated recycling protein
 10 (EARP), that ensure the proper tethering between endosomes and their acceptor compartment
 11 [53,54]. Both complexes cooperate with SNAREs for subsequent membrane fusion. GARP has
 12 been found to interact with RAB6A at the TGN [55] and EARP associates with RAB4-
 13 containing vesicles [54]. A previously unknown neurodevelopmental disorder linked to a
 14 mutation in yet another GARP/EARP subunit, VPS51, also appears to exist, based on our own
 15 observations (case report in preparation) as well as a BioRxive description of a 6-year-old
 16 patient with severe global developmental delay, pontocerebellar abnormalities, microcephaly,
 17 hypotonia, epilepsy and several systemic and peripheral dysfunctions (BioRxiv 409441, 2018).

18 A pontocerebellar hypoplasia caused by TBC1D23 mutations (PCH11; MIM #617695)
 19 has been shown in two different reports to be associated with POM or microcephaly of
 20 unknown onset, along with various other neurodevelopmental deficits and neurological signs
 21 (including a hypoplastic corpus callosum, as seen in several Golgipathic POMs, severe
 22 cognitive delays, motor weakness or lack of motricity, behavioral problems etc.) [56,57].
 23 TBC1D23, like TBC1D20 in Warburg-Micro syndrome, appears to be a RAB GAP (although
 24 neither its GTPase activity nor its RAB specificity has been clearly evidenced so far). It is
 25 localized at the *trans*-Golgi and regulated by the small GTPases ARL1 and ARL8, and appears
 26 to mediate the binding of endosomal vesicles to golgin-245 and golgin-97 on *trans*-Golgi

1 membranes to mediate retrograde transport [58]. It has been implicated in the regulation of
 2 neuronal migration/positioning during corticogenesis, as well as neurite/axon differentiation
 3 [56].

4 Autosomal recessive periventricular heterotopia with microcephaly (ARPHM; MIM
 5 #608097) has been described in several patients to be caused by *ARFGEF2* mutations. The
 6 microcephaly in these reports is progressive postnatally in three reports [59-61] and of
 7 unknown onset/progression in one [62]. The patients also display severe developmental delays
 8 and ID, epilepsy, brain atrophy and myelination delays associated with a thin corpus callosum.
 9 *ARFGEF2* encodes BIG2, a GTPase protein responsible for interior membrane trafficking in the
 10 *trans*-Golgi network and endosomes [63]. BIG2 interacts with RAB11, a *trans*-Golgi protein
 11 involved in diverse functions such as synaptic transmission, but also neuronal migration and
 12 axonal growth, functions that could explain the phenotypes seen in the reports above [64,65].

13 MEDNIK syndrome (MEDNIK; MIM #609313) is caused by mutations in *AP1S1*, a
 14 subunit of one of the five adaptor protein complexes (AP1-5), located at the *trans*-Golgi and in
 15 endosomes, that match cargo molecules, including neurotransmitters (and in the case of AP1S1,
 16 specifically, the copper pumps ATP7A and B) to their carriers (reviewed in [66]). Symptoms of
 17 MEDNIK syndrome, although predominantly cutaneous, include POM in addition to other
 18 typical neurological signs such as moderate to severe ID and deafness [67]. Montpetit and
 19 colleagues also mention the occurrence of peripheral neuropathy and microcephaly in the
 20 original French-Canadian cohort, without indicating age of onset, when discussing their animal
 21 model [68], although the original article by Saba and colleagues and subsequent discussions of
 22 this cohort only mention brain "atrophy" [67-69]. In addition, mutations in *AP1S2* cause
 23 Pettigrew syndrome (PGS, MIM #304340), an X-linked disorder characterized by ID, seizures,
 24 Dandy-Walker malformation and microcephaly, possibly postnatal, although head
 25 circumference was variable in the original family [70,71].

1 COG-associated Congenital Disorders of Glycosylation (CDGs) represent one subgroup
 2 of a very large family of multisystemic autosomal recessive pathologies involving dysfunctions
 3 in the processing of N- and O-linked glycans. While most of the mutations identified so far
 4 involve genes encoding glycosylation enzymes [72], the CDGs described in this paragraph are
 5 caused by defects in one of the 8 subunits of the Conserved Oligomeric Golgi (COG) complex,
 6 localized to the *cis*- and medial-Golgi as well as surrounding vesicles [73]. The COG complex
 7 is thought to act as a tethering factor, in particular during intra-GA and retrograde GA-to-ER
 8 trafficking, where it mediates the recycling of glycosyltransferases [74], suggesting that the
 9 incidence of CDG when COG subunits are mutated is likely due to the inability of these
 10 glycosylation enzymes to reach their target proteins [73]. COG-associated CDGs are associated
 11 with multiple neurological manifestations, including POM in patients carrying mutations in
 12 *COG1* (MIM #611209), *COG2* (MIM #617395), *COG4* (MIM #613489), *COG5* (MIM
 13 #613612), *COG7* (MIM #608779) and *COG8* (MIM #611182) [75-81]. Brain MRI has revealed
 14 hypoplasia of the corpus callosum in four patients [77,78] and brainstem atrophy in one case
 15 [75]. *COG6* mutations have also been associated with borderline POM in Shaheen syndrome
 16 (SHNS; MIM #615328) as well as a CDG with congenital microcephaly (MIM #614576)
 17 [82,83]. Interestingly, the COG complex has been shown to interact with molecules at all levels
 18 of GA organization and trafficking as well as a number of GA-associated RABs (see [4] for an
 19 overview).

20 Another family of GA-associated proteins whose mutation gives rise to a wide range of
 21 CDGs with neurological phenotypes is the solute carrier family 35 (SLC35), whose members
 22 carry a variety of molecules, mostly sugars, to the GA for the glycosylation of proteins.
 23 Mutations in *SLC35A3* have been associated with POM and ID [84] in a syndrome
 24 characterized by arthrogryposis, mental retardation and seizures (AMRS; MIM #615553).
 25 Similarly, mutations in *SLC35C1* give rise to CDG2C (MIM #266265), in which severe ID and
 26 POM have also been noted [85], while mutations in other family members give rise to various

1 CDGs with ID, microcephaly of unknown onset, and other neurological manifestations (e.g.
2 SLC35A1: CDG2F, MIM #603585; SLC35A2: CDG2M, MIM #300896).

3 Among CDGs caused by a defective trafficking mechanism, rather than an enzymatic or
4 metabolic deficiency, and including POM, psychomotor delays and white matter abnormalities
5 among their clinical signs, should be included CDG2K, caused by mutations in the
6 transmembrane GA protein TMEM165 (MIM #614727). While the exact function of this
7 protein is not yet known, it is probably an ion transporter that plays a role in pH, calcium or
8 manganese homeostasis, and mutations also appear to affect GA morphology [86,87].

9

10 II. Other microcephalies or macrocephalies related to impaired GA function

11 A number of other reports of patients with microcephalies linked to mutations in GA-
12 associated proteins exist in the literature. However, data on whether these microcephalies are
13 congenital or postnatal (or congenital but progressive after birth) is not always available.
14 Further studies might well turn up other syndromes where a POM or a progressive worsening
15 of microcephaly would indicate a defect in maturation (including trafficking or biosynthetic
16 defects) or other processes that take place later in development, such as gliogenesis, as opposed
17 to a congenital microcephaly that would indicate a deficit in the production of new neurons
18 earlier in development, even though these different microcephalies are likely to lie along the
19 same continuum rather than being mutually exclusive. The other side of the coin is that
20 mutations in several GA-related proteins appear to result in macrocephaly, possibly indicating
21 an opposite effect on the regulation of neurogenesis or neuronal apoptosis during maturation. A
22 few examples of these other microcephalies and macrocephalies linked to GA protein
23 mutations are given below (summarized in **Table 2**).

1 Mutations in the *WDR62* gene, which codes for a WD40 repeat protein highly expressed
 2 in the developing brain, cause autosomal recessive primary microcephaly 2 (MCPH2; MIM
 3 #604317) with seizures and ID in addition to congenital microcephaly [88,89]. Interestingly,
 4 even though it is best known for its presence at the centrosome during mitosis and appears to
 5 play a critical role in neuronal progenitor proliferation during corticogenesis, WDR62 also
 6 associates with GM130 and is localized at the GA during interphase, where its function is
 7 unknown [89]. Similarly, at least two other *MCPH* genes encode products that associate with
 8 the GA. *Autosomal recessive primary microcephaly 3* (MCPH3; MIM #604804) is related to
 9 mutations in the CDK5 regulatory subunit-associated protein 2, CDK5RAP2 [90], which plays
 10 an important role in progenitor division during neurogenesis [91,92]. Interestingly,
 11 CDK5RAP2 is necessary for microtubule nucleation and organization not only at the
 12 centrosome but also at the GA [93,94]. Similarly, we and others have found that *autosomal*
 13 *recessive primary microcephaly 17* (MCPH17; MIM #617090) is caused by mutations in the
 14 gene for the Citron Rho-interacting serine/threonine kinase, CIT [95,96]. The longer CIT-K
 15 protein, which localizes at the cleavage furrow and midbody during cell division (reviewed in
 16 [97]), is known from animal models to play a role in cytokinesis and progenitor survival during
 17 neurogenesis [98], while the shorter brain-specific isoform, CIT-N, is known to be enriched at
 18 the somatic GA of certain neurons as well as in dendrites where it interacts with peripheral
 19 Golgi outposts and plays a key role in the maintenance of dendritic spines [99,100].

20 Mutations in TRAPPC11, a subunit of the TRAPP complex that plays a role in ER-GA
 21 trafficking and activates several RABs, as described above, lead to a limb girdle muscular
 22 dystrophy (LGMDR18; MIM #615356) with microcephaly of unknown onset, myopathy,
 23 infantile hyperkinetic movements, ataxia, and ID [101,102].

24 A microcephalic dwarfism syndrome (SRMMD; MIM #617164) characterized by, in
 25 addition to microcephaly, facial dysmorphism, severe micrognathia, rhizomelic shortening and

1 mild developmental delay has been associated with heterozygous mutations in *ARCNI* [103].
 2 *ARCNI* (*COPD*) encodes Archain 1, the delta subunit of the vesicular coat protein COPI,
 3 necessary for both intra-GA and GA-ER retrograde transport, and *ARCNI* haploinsufficiency
 4 leads to COPI-mediated transport defects. In addition, a hypomorphic missense mutation in the
 5 *COPB2* gene, encoding the beta subunit of COPI, has also recently been found to be the cause
 6 of a primary autosomal recessive microcephaly (MCPH19; MIM #617800) in which the
 7 congenital microcephaly is associated with severe developmental delay, cortical blindness and
 8 spasticity [104]. *COPB2* appears to be involved not only in retrograde GA-ER transport,
 9 possibly interacting with DYMECLIN [7], but in early neuronal proliferation and apoptosis
 10 [104].

11 *A PEHO (progressive encephalopathy with edema, hypsarrhythmia and optic atrophy) -*
 12 *like syndrome* (PEHOL; MIM #617507) caused by a mutation in the *CCDC88A* gene coding
 13 for GIRDIN, a coiled-coil GA protein, shows, in addition to profound psychomotor delay,
 14 seizures and progressive brain atrophy, severe congenital microcephaly in all patients, and
 15 dysmyelination in one case [105]. GIRDIN, also known as KIAA1212, appears to be involved
 16 in the migration and positioning of new neurons, controlling soma size and dendritic branching
 17 [106].

18 *AP4-deficiency syndrome* is caused by a mutation in a subunit of another of the five
 19 adaptor protein complexes, AP1-5, mentioned above (reviewed in [66]). AP4-deficiency
 20 syndrome, which includes a very large range of phenotypes, may be included among the large
 21 number of hereditary spastic paraplegias [107]. Among them, *AP4E1* mutations (MIM
 22 #613744) lead to a form of hereditary spastic paraplegia with congenital microcephaly, ID, thin
 23 corpus callosum, psychomotor deficits and spasticity [108-110], which Moreno-de-Luca and
 24 colleagues found to be similar to another hereditary spastic paraplegia caused by mutations in
 25 *AP4M1* (MIM #612936), in which several patients displayed microcephaly in addition to other

1 neurological signs [111]. Similarly, Abou Jamra and colleagues also found microcephaly, along
2 with a variety of other symptoms in patients with *AP4B1* (MIM #614066) and *AP4S1* mutations
3 (MIM #614067) [108]. Surprisingly, microcephaly of unknown onset associated with ID has
4 also been noted in *Hermansky-Pudlak syndrome 2* (HPS2; MIM #608233), not commonly
5 thought to be associated with neurodevelopment; in this disorder, mutations in *AP3B1*
6 principally lead to oculocutaneous albinism, immunodeficiency and hematological
7 abnormalities [112].

8 As in the case of the TRAPP and AP protein families, mutations in another SLC family
9 member, *SLC9A6*, are also associated with other forms of microcephaly (congenital,
10 progressive, or of unknown onset) and severe ID in the X-linked mental retardation known as
11 *Christianson syndrome* (MRXSCH; MIM #300243) [113-115].

12 *In an early infantile epileptic encephalopathy* (EIEE49, MIM #617281) caused by
13 mutations in *DENND5A*, a gene encoding a GA-localized GTPase activator thought to play a
14 role in neuronal differentiation, almost all affected individuals show microcephaly in addition
15 to various other neurological signs, including seizure onset in the neonatal period, global
16 developmental delay with ID and lack of speech, hypotonia, spasticity etc. [116,117].
17 *DENND5A* acts as a GEF for the neuronal GA-specific GTPase *RAB39* [118], which is
18 involved in regulating the number and morphology of neurite growth cones and in synapse
19 formation and maintenance, including alpha-synuclein homeostasis. However, deficits in
20 *RAB39B* are also associated with an *X-linked form of ID* with macrocephaly rather than
21 microcephaly (MRX72; MIM #300271) [119,120]. Macrocephaly is also a feature of *RAB39B*-
22 associated early-onset Parkinsonism or *Waisman syndrome* (WSMN; MIM #311510)
23 [121,122].

24 Mutations in another GTPase activator, *HERC1*, which is localized to the cytoplasm and
25 GA/vesicular compartments and acts as a GEF for *ARF1*, and possibly *RAB3A* and *RAB5*

1 [123], also result in a macrocephaly syndrome with dysmorphic facies and psychomotor
2 retardation (MDFPMR; MIM #617011) [124-126].

3 Similarly, in autosomal dominant mental retardation 48 (MRD48; MIM #617751)
4 mutations in the gene encoding the small Rho GTPase RAC1, which appears to interact with
5 various GA proteins and to play a distinct role in neuronal progenitor proliferation, lead to ID
6 with either microcephaly or macrocephaly, as well as a developmental delay, seizures, absent
7 speech and a number of defects on MRI [127]. Interestingly, *SPATA13* (also known as *ASEF2*),
8 encoding a GEF for both RAC1 and CDC42 (involved in Takenouchi-Kosaki syndrome, as
9 mentioned above) that is enriched in the prenatal frontal cortex and plays a role in dendritic
10 spine formation and cell migration, possibly by regulating actin cytoskeletal remodeling
11 [128,129], is among a set of 26 newly identified ID genes [130].

12 Another GA-associated gene implicated in corticogenesis is the gene for the
13 pseudokinase STRADA (also known as STE20 related kinase adaptor alpha, or LYK5),
14 deletions in which give rise to macrocephaly in a syndrome encompassing polyhydramnios,
15 megalencephaly and symptomatic epilepsy (PMSE; MIM #611087) [131,132]. STRADA
16 appears to form a complex with STK25 and the golgin GM130 to regulate GA morphology and
17 positioning, thus controlling neuronal differentiation and integration during development [133].

18

19 III. GA protein mutations associated with other neurodevelopmental anomalies

20 Not all GA proteins appear to be associated with microcephalic or macrocephalic
21 syndromes when mutated. However, a number of GA proteins do have other significantly
22 neurodevelopmental effects involving either the central or peripheral nervous system, and lead
23 to phenotypes that include ID, ataxias, peripheral neuropathies or sensorineural loss. Some of
24 these are described below, and also summarized in **Table 3** (excluding GA-localized enzymes

1 whose role lies primarily in protein or lipid biosynthesis/modification, and that are thus likely
2 to have metabolic effects rather than mechanistic ones).

3 Many GA proteins other than those described in Sections I and II above are implicated
4 in various forms of ID, even without being associated with microcephaly or macrocephaly. For
5 example, mutations in the RAB-GDP dissociation inhibitor GDI1 are responsible for a non-
6 syndromic X-linked form of ID (MRX41/MRX48; MIM #300849) [134-136].

7 A non-RAB molecular partner of BIG2 (*ARFGEF2*), which, as we have discussed
8 above, causes a periventricular heterotopia and progressive microcephaly, is another GA
9 protein, FILAMIN alpha (FLNA), that plays a role in neuronal migration by regulating the
10 relocation of BIG2 and the activation of ARF1 at the cell membrane [137]. Mutations in
11 *FLNA* lead to X-linked periventricular nodular heterotopia (PVNH1; MIM #300049),
12 characterized by brain structural abnormalities and ID, at least in males, but with no known
13 microcephaly (reviewed in [138]).

14 Mutations in the gene for phosphofurin acidic cluster sorting protein, PACS1, a *trans-*
15 Golgi protein involved in the trafficking of FURIN, lead to Schuurs-Hoeijmakers syndrome, an
16 autosomal dominant mental retardation (MRD17; MIM #615009), characterized by ID,
17 dysmorphic features, and brain MRI defects in addition to skeletal defects [139].

18 Similarly, autosomal recessive mutations in *SCYL1*, which encodes a protein located at
19 the interface between the GA and COPI-coated vesicles and likely involved in trafficking
20 functions, lead to another form of autosomal recessive spinocerebellar ataxia (SCAR21; MIM
21 #616719), characterized by cerebellar atrophy, peripheral neuropathy and mild ID [140].

22 Several mutations in the *BICD2* gene, which encodes the golgin BICAUDAL2 that
23 interacts with the dynein-dynactin motor complex and RAB6A, have been shown to cause an
24 autosomal dominant form of spinal muscular atrophy (SMALED2; MIM #615290) [141-143].

1 Similarly, mutations in *KIF1C*, a kinesin family motor protein that interacts with RAB6 to
2 mediate GA tethering [144], lead to an autosomal recessive form of hereditary spastic
3 paraplegia, spastic ataxia 2 (SPAX2; MIM #611302) [145-147].

4 Mutations in the *TANGO2* gene, which encodes a protein thought to be involved in
5 loading cargo into vesicles at the ER but is also localized at the GA, lead to a complex
6 syndrome characterized by metabolic encephalomyopathic crises, recurrent, with
7 rhabdomyolysis, cardiac arrhythmias, and neurodegeneration (MECRCN; MIM #616878),
8 with multiple neurodevelopmental manifestations including seizures and ataxia [148,149].

9 Mutations in *GOSR2*, a GA SNARE complex member, lead to early-onset ataxia and
10 progressive myoclonic epilepsy (EPM6; MIM #614018) in childhood and skeletal deformities
11 by adolescence [150,151].

12 A *cis*-Golgi protein encoded by *RETREG1* or *FAM134B* has been found to be mutated
13 in hereditary sensory and autonomic neuropathy type IIB (HSAN2B; MIM #613115),
14 characterized by childhood onset autonomic neuropathy, and heavily impaired sensory and
15 sometimes motor function [152].

16 Among the GA-associated genes involved in sensorineural loss, *OSBPL2*, which
17 encodes a fatty-acid receptor, oxysterol binding protein-like protein 2, is mutated in a
18 nonsyndromic autosomal dominant form of deafness with childhood onset (DFNA67; MIM
19 #616340) [153,154]. In Hermansky-Pudlak syndrome 1 (HPS1, MIM #203300), a syndrome
20 usually characterized in humans by albinism and excessive bleeding, as in HPS2 (discussed in
21 Section II), mutations in the AP3D1 adaptor complex subunit give rise to a phenotype hearing
22 loss in addition to neurodevelopmental delay and generalized seizures (HSP10; MIM #617050)
23 [155]. Several of the genes and syndromes described above also have an impact on vision
24 (several AP and COG subunits, RAB3GAP2, and TBC1D20, to name a few).

1 Sometimes, mutations in GA genes that are not thought to be associated with
2 neurological symptoms might in fact have unnoticed neurodevelopmental effects, as in the case
3 of the Hermansky-Pudlak syndromes, as seen above. In other cases, disorders considered to be
4 neurodegenerative might have a neurodevelopmental component in rare early onset forms, such
5 as some spinocerebellar ataxias: type 2 (MIM #183090, *ATXN2*), type 5 and 14 (MIM
6 #600224; MIM #615386, *SPTBN2*) and type 8 (MIM #610743, *SYNE1*) [156].

7 The GA also plays an essential role in the biosynthesis or modification of the cargo
8 being transported. While these are generally considered to be "metabolic" disorders and are
9 related more to the modification of trafficked molecules than to trafficking per se, mutations in
10 many of these also have neurodevelopmental consequences (for a brief overview, see [72]). For
11 instance, it is the site of synthesis of some glycolipids and sphingomyelin, a major component
12 of myelin and essential for normal morphogenesis or plasticity of membrane-rich cell types
13 such as neurons (during migration, rapid axonal growth or dendritic arborization etc.) or
14 oligodendrocytes (for the generation of the myelin sheath), from lipid precursors synthesized in
15 the ER (glycerol phospholipids, cholesterol and ceramide). Mutations in genes involved in lipid
16 biosynthesis and processing have also been associated with several neurodevelopmental
17 defects. For example, a mutation in *ACER3*, encoding an ER and Golgi ceramidase involved in
18 sphingolipid metabolism, has been identified in a family with progressive impairment and
19 regression of neurodevelopment during the first year of life, leukodystrophy-like signs and
20 peripheral neuropathy (PLDECO, MIM #617762) [157]. Another GA gene involved in lipid
21 metabolism and that leads to neurodevelopmental deficits is that encoding DDHD domain
22 containing 2 (*DDHD2*), a phospholipase with a major role in brain triglyceride metabolism
23 [158], mutations in which result in hereditary spastic paraplegia type 54 (SPG54, MIM
24 #615033) [159]. Mutations in the *PGAP2* and *PGAP3* genes (post-GPI attachment to proteins 2
25 and 3), which are essential for the glycolipid remodeling of GPI anchor proteins, have been
26 associated with developmental delays and ID, in addition to microcephaly in several families

1 (HPMRS3, MIM #614207 and HPMRS4, MIM #615716) [160-164], while *PGAPI* has also
2 been linked to ID [165,166].

3 Among the cargo-modifying enzymes present in the GA are a very large complement of
4 different glycosyltransferases and glycosidases, in addition to enzymes responsible for adding
5 or removing phosphate, sulphate, lipid and other groups from proteins. To give a few examples,
6 mutations in the acetylglucosaminyltransferase gene *MGAT2*, a member of the N-glycosylation
7 pathway, lead to CDG type IIa (CDG2A, MIM #212066), characterized by seizures,
8 developmental delays and ID in addition to other symptoms [167]. Another member of the N-
9 glycosylation pathway is β 1,4 galactosyltransferase I, implicated in severe forms of CDG-IId
10 (CDG2D, MIM #607091) with neurological deficits, hydrocephalus, myopathy and defective
11 blood clotting [168]. CDG type II is also caused by mutations in the mannosidase gene
12 *MAN1B1*, which lead to a syndrome characterized by ID and truncal obesity, while *INPP5E*
13 (inositol polyphosphate-5-phosphatase E) mutations have been implicated in the
14 neurodevelopmental disorders Joubert (JBTS1, MIM #213300) and MORM syndromes
15 (MORMS, MIM #610156) [169,170], the latter of which also includes ID and truncal obesity.
16 Several types of muscular dystrophy with neurological involvement are also caused by defects
17 in GA glycosylation genes (e.g. FKR1P, LARGE, POMGnT1). Similarly, a variety of members
18 of the solute carrier families (SLC), which transport various metabolites (sugars, acetylCoA,
19 zinc...) are involved in CDGs and other neurodevelopmental disorders including spastic
20 paraplegias, ID, epilepsy etc [2].

21 Another GA protein family is that of the copper-transporting P-type ATPases, ATP7A
22 and B (reviewed in [171]), which are specifically trafficked by AP1S1, whose mutation causes
23 MEDNIK syndrome (mentioned in Section I above). Under basal conditions, ATP7A and B,
24 which are ion pumps, are located in the *trans*-Golgi network (TGN) and translocates copper
25 across intracellular membranes into the secretory pathway for incorporation into copper-

1 dependent enzymes. Their mutation, while having multisystemic consequences due to copper
2 deposition in the liver and skin, for example, in addition to the brain, has been linked to
3 Menkes disease (MNK, MIM #309400) or occipital horn syndrome (OHS, MIM #304150), or
4 spinal muscular atrophy (SMA3, MIM #300489) (ATP7A), all disorders with a childhood
5 onset, or dystonia and neurodegeneration of either childhood or late onset (ATP7B).

6

7 **The link between Golgipathies, GA function and neurodevelopment**

8 What is the explanation for the exceptionally large spectrum of diseases and symptoms
9 associated with defective GA proteins above, even when one limits the discussion to those with
10 neurodevelopmental consequences?

11 The GA is not only involved in but lies at the crossroads of a number of distinct and
12 crucial cellular processes, some of which have only recently begun to be elucidated. In
13 addition, individual GA proteins themselves often participate in more than one function or
14 pathway, depending on the cellular context, developmental stage and the pathophysiological
15 state, and some proteins, such as the small RAB GTPases, belong to extended families with a
16 whole gamut of functions, both within and outside the GA. However, much is still unknown
17 regarding the precise functions and the molecular partners of the great majority of GA proteins,
18 and existing information often comes from lower species or organs outside the nervous system.
19 Despite these overlaps and restrictions, obtaining even an incomplete understanding of some of
20 these functions and proteins may provide insights into the complex repercussions of their
21 mutation or deregulation, including the various neurodevelopmental processes impacted.
22 **Figure 1** illustrates the relationship between some of the principal GA functions and the
23 different stages of neurodevelopment in which they are implicated, taking the central nervous
24 system as an example. Understanding these functions and how they evolve over the lifespan of
25 the cell and the organism would also help elucidate the reason why mutations in some families

1 of GA proteins appear to cause a spectrum of deficits rather than discrete phenotypic entities
2 (e.g. both congenital microcephalies and POM in the case of defective TRAPP, AP or SLC
3 complex subunits).

4 Maintenance of GA structure, integrity and position:

5 A distinctive characteristic of the GA in the cells of mammals and other vertebrates is
6 its structure – it is made up of stacks of flattened cisternae, as in protists, plants and
7 invertebrates, but these stacks are linked to each other to form a "ribbon" [172,173]. Cisternal
8 stacking is necessary for normal trafficking, while the ribbon structure is thought to play a role
9 in higher order functions such as mitosis and apoptosis, cell polarity/migration and stress
10 responses (reviewed in [174,175]). A number of GA proteins are involved in regulating this
11 typical structure and the integrity of the GA. Prominent among these are various members of
12 the coiled-coil golgin family of proteins (e.g. GM130, GIANTIN, P115, GOLGIN-45,
13 GMAP210, GIRDIN etc.), many of which interact with coiled-coil GRASP proteins and small
14 GTPases or GTP-binding proteins of the RAB, ARF and ARL families to control cisternal
15 structure and stacking in the GA. (reviewed in [174-176]). Many of the GA-associated
16 GTPases are in turn regulated by families of regulatory proteins, such as the GEFs and GAPs,
17 which act at various points and target effector molecules in the trafficking pathway. Among the
18 GA-associated members of these large families of proteins, some are specifically expressed in
19 neural tissue, for example RAB6B [177] and to some extent RAB6C [178]. Several golgins
20 (e.g. Bicaudal D and GMAP210) and RAB GTPases (for instance, the multifunctional RAB6)
21 are involved in interactions between the GA and the microtubule cytoskeleton, including
22 molecular motors such as DYNEIN, and help in the organization of the GA ribbon by
23 recruiting GA stacks to the microtubule organizing center (MTOC). Some, such as GM130,
24 through their interactions with other polarity-determining kinases as well as their role in
25 microtubule nucleation and organization [179-182], dictate the polarity of the GA and thus of

1 the cell or neuron as a whole [183], thus controlling its correct differentiation and function. The
2 fragmentation of the GA ribbon through the phosphorylation of the GRASPs and other
3 molecules might also allow GA repositioning and thus migration, growth or differentiation
4 [184] (fragmentation is also essential for the progression of the cell cycle, discussed below). In
5 addition to structural changes, GM130 and GRASP65 also form part of signaling cascades that
6 regulate cell migration [181].

7 Secretory and membrane trafficking:

8 GA structure and integrity and many of the large array of molecules that control them
9 are also essential for the various steps involved in vesicular transport – coat components and
10 adaptors that control vesicle targeting and recognition, the coiled-coil golgins necessary for
11 their capture and the SNAREs and COGs that help in tethering and fusion, RAB and other
12 small GTPases that mediate the choreographed attachment and detachment of molecules at
13 each step, adaptors, activators and inhibitors for each of the above etc. Interfering with these
14 proteins or their interactions results in disrupted GA structure/organization and abnormal
15 protein and lipid transport (see for example the effects of disrupting various RABs on GA
16 structure, reviewed in [185]), important for both neuronal and oligodendrocyte function,
17 including the rapid membrane expansion needed for the establishment of neuronal outgrowth
18 and connectivity and myelination. Mutations in these genes are involved in a number of
19 Golgipathies with diverse symptoms, including the large majority of the POM syndromes with
20 white matter defects that we have listed above (Dyggve-Melchior-Clausen syndrome, Warburg-
21 Micro and Martsolf Syndromes, Cohen Syndrome Progressive Cerebello-Cerebral Atrophy
22 Type 2 and other Pontocerebellar Hypoplasias, microcephalies related to mutations in the
23 TRAPP complex and COG-related CDGs, to name a few) as well as a range of spinal muscular
24 atrophies and paraplegias. Other functional consequences could be the disruption of neuronal
25 migration to the appropriate target layers or regions, as a consequence both of membrane

1 trafficking deficits and the disruption of the MTOC function of the GA and thus of cellular
2 polarity [4]. Certain syndromes characterized by epilepsy or seizures could thus be a result of
3 either the aberrant connectivity caused by such migration defects, or the defective transport of
4 neurotransmitters or their receptors/inhibitors to the synapse. Additionally, the occurrence of
5 central hypogonadism, dwarfism, obesity etc. of unknown etiology in certain POM
6 Golgipathies could conceivably be due to deficits in neuroendocrine secretory activity
7 controlling bodily hormonal homeostasis.

8 Cell cycle regulation:

9 Closely related to the structure and position of the GA is its role in the cell cycle. The
10 typical ribbon structure of the GA in mammalian cells is usually localized close to the
11 centrosome, a position regulated among others by a number of GA-associated proteins,
12 including those involved in its structure and trafficking function (see for review [186]). During
13 mitosis, the GA loses its pericentriolar position, as it does its ability to function as an
14 independent MTOC, and undergoes fragmentation to yield small tubular-reticular structures
15 and dispersed vesicles. While GA fragmentation could be considered a logical prerequisite for
16 the partitioning of the GA into the daughter cells, it appears that GA fragmentation is in fact a
17 prerequisite for mitosis itself, and blocking GA fragmentation, for example by blocking
18 GRASP phosphorylation, acts as a "Golgi checkpoint" for the progression of mitosis [187-189].
19 Failure of the GA to fragment results in the failure of Aurora-A recruitment at the centrosome,
20 essential for mitosis [190]. Several other GA proteins (for example GM130 and golgin-84) as
21 well as non-GA proteins are also activated during fragmentation. In addition, a number of RAB
22 GTPases including several GA-associated RABs, as well as the small G-protein ARF1 along
23 with its activators and effectors, play essential roles at various steps of mitosis. Surprisingly,
24 several GA proteins acquire new locations and functions during mitosis (reviewed in [188]).
25 Some GA proteins, such as GM130, whose role in this regard has been described above, may

1 also play very specific roles in neurogenesis and neural progenitor division, by influencing cell
2 polarity (reviewed in [191]) or the symmetry of mitosis, which plays a crucial role in the
3 generation of different types of neuronal progenitors while still maintaining the pool of stem
4 cells. For example, the asymmetric division of neural progenitor cells requires the interaction of
5 the golgin GCP60 (also known as ACBD3 or PAP7) and Numb [192]. While the
6 pathophysiological mechanisms underlying the syndromes characterized by macrocephaly
7 mentioned above are not clear, most of the mutations detected result in a loss of function, and it
8 is conceivable that uncontrolled proliferation or the dysregulation of the timing of symmetric
9 versus asymmetric divisions during neurogenesis, could lead to the overproduction of certain
10 neurons. In another instance of the overlap between the trafficking function of the GA and its
11 role in neurogenesis, the *trans*-Golgi BIG2 protein encoded by *ARFGEF2*, essential for protein
12 trafficking, is also involved in normal neural progenitor cell proliferation, migration and axonal
13 growth in the developing mammalian cortex through its interaction with RAB11, another *trans*-
14 Golgi protein. The early microcephaly and aberrant corticogenesis noted in ARPHN, caused by
15 *ARFGEF2* mutations [59-62], could for example be due to defective neurogenesis and
16 migration rather than defects in neuronal maturation or myelination.

17 It should not be forgotten that mutations in GA proteins whose function is essential
18 early in neurodevelopment, for example during neurogenesis, might simply be embryonic lethal
19 and thus pass unremarked.

20 *Autophagy and apoptosis:*

21 At the other end of the spectrum from cell proliferation and membrane expansion, the
22 GA is also involved in normal or pathological cell death or the destruction of cellular contents.
23 Both apoptosis and autophagy are normally occurring processes by which unwanted cells or
24 cellular components are eliminated while limiting tissue damage (i.e. leakage of cellular
25 contents). They occur during neurodevelopment, when the large excess of new neurons or

1 membranes produced is culled during the maturation of the CNS. In addition, they are also
2 brought into play for the removal of damaged cells during conditions of stress or disease. In
3 fact, the GA is increasingly thought to play a role in sensing stress and reestablishing cellular
4 homeostasis; prolonged "Golgi stress", like ER stress, while not due to an intrinsic GA defect,
5 nevertheless leads to impaired or abnormal GA function, contributing to pathogenesis and cell
6 death, including by novel mechanisms other than apoptosis [193].

7 In autophagy, or more specifically, macroautophagy, cellular contents to be degraded
8 are enveloped in a "phagophore" or "isolation membrane" and delivered to acidic lysosomes for
9 destruction. There is evidence that the phagophore might bud directly from GA membranes, or
10 alternatively, from the ER or ER-Golgi Intermediate Compartment [194,195]. The GA might
11 additionally be directly involved in the degradation of undesirable cellular contents [196].
12 Several GA-associated RAB GTPases and their partners, normally involved in various stages of
13 trafficking, also play key roles in the formation of the autophagosome [197-201], as do
14 SNAREs, which are involved in autophagosome fusion (reviewed in [202]). Among other GA
15 proteins, BECLIN1, a *trans*-Golgi protein involved in endosome-to-GA recycling, also plays a
16 crucial early role in autophagosome formation (reviewed in [203]), by interacting with
17 UVRAG, which normally mediates GA-to-ER retrograde transport by tethering COPI-coated
18 vesicles but is displaced during autophagy [204]. Similarly, the *trans*-Golgi membrane-bound
19 protein ATG9 is found in vesicles that contribute to autophagosome formation [199], and the
20 regulation of its trafficking plays a crucial role in the induction of autophagy pathways
21 [205,206]. Several coat adaptor proteins of the AP1, 2 and 4 classes are known to interact with
22 ATG9, and are also necessary for autophagosome formation [207,208].

23 Apoptosis, resulting from mitochondrial membrane permeabilization in response to
24 internal or external signals and leading cell death by strictly regulated molecular and cellular
25 mechanisms, is mediated by members of the caspase and BCL-2 families of proteins. Much of

1 the evidence for the involvement of GA proteins in apoptosis comes from neurodegenerative
2 disorders such as Alzheimer, Parkinson and Huntington Diseases, where the GA undergoes
3 stress due to an accumulation of aberrant and misfolded proteins or peptides, also causing it to
4 fragment (reviewed in [209-211]). However, some of the early machinery for apoptosis localize
5 to the GA, and is involved in cleaving various GA proteins that also play a role in
6 neurodevelopment (for example GRASP65, GM130 or GIANTIN). Their cleavage triggers the
7 mitosis-like disassembly of the GA and subsequent apoptosis (reviewed in [212]). Some GA
8 proteins also have a larger signal transduction role – GMAP210 and golgin-160 as well as
9 cleaved p115 fragments are translocated to the nucleus during apoptosis, triggering further
10 apoptotic changes [213,214]. It is certainly possible that mutations that interfere with the
11 cleavage of such GA proteins or that lead to the production of truncated proteins would either
12 curtail or augment apoptosis, with consequences for neurodevelopment ranging from
13 insufficient neurogenesis to excess neurons that are not culled and that lead to macrocephaly,
14 aberrant connectivity and related disorders.

15 *Biosynthesis and processing of lipids and proteins:*

16 As mentioned previously, the GA is also intimately involved in the post-translational
17 modification of proteins and the biosynthesis of some lipids. In terms of the physiological
18 effects of mutations in these proteins versus mutations in proteins involved in trafficking per se,
19 there might be a convergence, since the functional consequences of the lack of delivery of a
20 modified protein to its target intracellular compartment and the lack of its modification in the
21 first place are likely to be similar in at least some respects. In addition, the highly specialized
22 nature of the nervous system implies a corresponding adaptation of GA trafficking function in
23 the component cells (for example, the occurrence of Golgi outposts in dendrites), and
24 correspondingly, defects in GA enzyme function often lead to neurological consequences (also
25 reviewed in [2,4]). A prime example of this convergence is provided by the CDGs, which could

1 be related to structural/mechanical deficits (e.g. due to the mutation of COG subunits necessary
2 for vesicle tethering) or due to enzymatic deficits (due to the failure of glycosylation).

3

4 **Conclusion**

5 While the large number of neurodevelopmental Golgipathies described in this review
6 contain some surprises, it appears as if the majority were, and are, simply hiding in plain sight.
7 The GA is involved in a very large range of functions spanning every stage of a cell's lifespan;
8 an even larger number of overlapping GA-associated proteins and pathways carry out or
9 regulate these functions. It is therefore to be expected that as our knowledge of these proteins
10 and pathways grows, and as modern sequencing methods provide a molecular diagnosis for
11 more obscure syndromes, the range of phenotypes that we know to be caused by defective GA
12 proteins and their partners will expand. This is especially true when one considers the essential
13 roles played by the GA in the formation, growth and maturation of the brain and nervous
14 system. In fact, the spectrum of syndromes in which mutations in GA-associated proteins are
15 implicated, and the overlap in the cellular roles played by these proteins, evoke the intriguing
16 idea that the GA might modify its role in keeping with the needs of the cell or the organism
17 during its lifespan. For instance, the same proteins that are actively involved in cell cycle
18 initiation or regulation during neurogenesis, when abundant proliferation is required, might be
19 repurposed to lend a hand in neuronal migration, apoptosis or maturation, meet secretory
20 trafficking needs during synaptogenesis and myelination as well as normal cellular function for
21 the major part of the lifespan of the cell, and finally play a role in repair and damage control
22 during aging (see also [215]). From this perspective, this vast array of neurodevelopmental
23 Golgipathies appears not as isolated syndromes that differ from each other, but as points that
24 fall along a few key functional continua, with flexible phenotypes that primarily reflect the

1 developmental stage at which function is interrupted or altered. Such an organelle-centric
2 approach might eventually make it easier to understand the pathophysiology of these disorders.

3

4 **Acknowledgements**

5 We are grateful to Cécile Martel for invaluable support. This work was supported by the
6 Institut National pour la Santé et la Recherche Médicale (INSERM), the Centre National de la
7 Recherche Scientifique (CNRS), the Université Paris 7, DHU PROTECT, and European and
8 national grants from the French National Research Agency (ANR-13-RARE-0007-01 to AV,
9 SP and VEG (ERA-NET E-Rare 2013, EuroMicro project), ANR-15-NEUR-0003-01 to PG
10 (ERA-NET Neuron, MicroKin project), and ANR-16-CE16-0024-01 to VEG (PRC
11 GNERIQUE 2016, MicroGol project).

12

13 **Conflict of Interest**

14 The authors declare no conflicts of interest

15

1 **References**

- 2 1 Golgi C: On the structure of nerve cells. 1898. *Journal of microscopy* 1989;155:3-7.
- 3 2 Zappa F, Failli M, De Matteis MA: The Golgi complex in disease and therapy. *Curr Opin Cell Biol*
- 4 2018;50:102-116.
- 5 3 Hanus C, Ehlers MD: Specialization of biosynthetic membrane trafficking for neuronal form and
- 6 function. *Curr Opin Neurobiol* 2016;39:8-16.
- 7 4 Passemard S, Perez F, Colin-Lemesre E, Rasika S, Gressens P, El Ghouzzi V: Golgi trafficking
- 8 defects in postnatal microcephaly: The evidence for "Golgipathies". *Prog Neurobiol* 2017;153:46-63.
- 9 5 Dupuis N, Fafouri A, Bayot A, Kumar M, Lecharpentier T, Ball G, Edwards D, Bernard V,
- 10 Dournaud P, Drunat S, Vermelle-Andrzejewski M, Vilain C, Abramowicz M, Desir J, Bonaventure J,
- 11 Gareil N, Boncompain G, Csaba Z, Perez F, Passemard S, Gressens P, El Ghouzzi V: Dymeclin deficiency
- 12 causes postnatal microcephaly, hypomyelination and reticulum-to-Golgi trafficking defects in mice and
- 13 humans. *Hum Mol Genet* 2015;24:2771-2783.
- 14 6 Dimitrov A, Paupe V, Gueudry C, Sibarita JB, Raposo G, Vielemeyer O, Gilbert T, Csaba Z, Attie-
- 15 Bitach T, Cormier-Daire V, Gressens P, Rustin P, Perez F, El Ghouzzi V: The gene responsible for Dyggve-
- 16 Melchior-Clausen syndrome encodes a novel peripheral membrane protein dynamically associated
- 17 with the Golgi apparatus. *Hum Mol Genet* 2009;18:440-453.
- 18 7 Osipovich AB, Jennings JL, Lin Q, Link AJ, Ruley HE: Dyggve-Melchior-Clausen syndrome:
- 19 chondrodysplasia resulting from defects in intracellular vesicle traffic. *Proc Natl Acad Sci U S A*
- 20 2008;105:16171-16176.
- 21 8 Paupe V, Gilbert T, Le Merrer M, Munnich A, Cormier-Daire V, El Ghouzzi V: Recent advances in
- 22 Dyggve-Melchior-Clausen syndrome. *Mol Genet Metab* 2004;83:51-59.
- 23 9 Goud B, Gleeson PA: TGN golgins, Rabs and cytoskeleton: regulating the Golgi trafficking
- 24 highways. *Trends in cell biology* 2010;20:329-336.
- 25 10 Koreishi M, Gniadek TJ, Yu S, Masuda J, Honjo Y, Satoh A: The golgin tether giantin regulates
- 26 the secretory pathway by controlling stack organization within Golgi apparatus. *PLoS One*
- 27 2013;8:e59821.
- 28 11 Rosing M, Ossendorf E, Rak A, Barnekow A: Giantin interacts with both the small GTPase Rab6
- 29 and Rab1. *Experimental cell research* 2007;313:2318-2325.
- 30 12 Cohn DH, Ehtesham N, Krakow D, Unger S, Shanske A, Reinker K, Powell BR, Rimoin DL: Mental
- 31 retardation and abnormal skeletal development (Dyggve-Melchior-Clausen dysplasia) due to
- 32 mutations in a novel, evolutionarily conserved gene. *Am J Hum Genet* 2003;72:419-428.
- 33 13 Alshammari MJ, Al-Otaibi L, Alkuraya FS: Mutation in RAB33B, which encodes a regulator of
- 34 retrograde Golgi transport, defines a second Dyggve-Melchior-Clausen locus. *J Med Genet*
- 35 2012;49:455-461.
- 36 14 Dupuis N, Lebon S, Kumar M, Drunat S, Graul-Neumann LM, Gressens P, El Ghouzzi V: A Novel
- 37 RAB33B Mutation in Smith-McCort Dysplasia. *Hum Mutat* 2013;34:283-286.
- 38 15 Warburg M, Sjo O, Fledelius HC, Pedersen SA: Autosomal recessive microcephaly, microcornea,
- 39 congenital cataract, mental retardation, optic atrophy, and hypogenitalism. *Micro syndrome. Am J Dis*
- 40 *Child* 1993;147:1309-1312.
- 41 16 Bem D, Yoshimura S, Nunes-Bastos R, Bond FC, Kurian MA, Rahman F, Handley MT, Hadzhiev Y,
- 42 Masood I, Straatman-Iwanowska AA, Cullinane AR, McNeill A, Pasha SS, Kirby GA, Foster K, Ahmed Z,
- 43 Morton JE, Williams D, Graham JM, Dobyns WB, Burglen L, Ainsworth JR, Gissen P, Muller F, Maher ER,
- 44 Barr FA, Aligianis IA: Loss-of-function mutations in RAB18 cause Warburg micro syndrome. *Am J Hum*
- 45 *Genet* 2011;88:499-507.
- 46 17 Handley MT, Morris-Rosendahl DJ, Brown S, Macdonald F, Hardy C, Bem D, Carpanini SM,
- 47 Borck G, Martorell L, Izzi C, Faravelli F, Accorsi P, Pinelli L, Basel-Vanagaite L, Peretz G, Abdel-Salam
- 48 GM, Zaki MS, Jansen A, Mowat D, Glass I, Stewart H, Mancini G, Lederer D, Roscioli T, Giuliano F,
- 49 Plomp AS, Rolfs A, Graham JM, Seemanova E, Poo P, Garcia-Cazorla A, Edery P, Jackson IJ, Maher ER,
- 50 Aligianis IA: Mutation spectrum in RAB3GAP1, RAB3GAP2, and RAB18 and genotype-phenotype
- 51 correlations in warburg micro syndrome and Martsolf syndrome. *Hum Mutat* 2013;34:686-696.

- 1 18 Liegel RP, Handley MT, Ronchetti A, Brown S, Langemeyer L, Linford A, Chang B, Morris-
2 Rosendahl DJ, Carpanini S, Posmyk R, Harthill V, Sheridan E, Abdel-Salam GM, Terhal PA, Faravelli F,
3 Accorsi P, Giordano L, Pinelli L, Hartmann B, Ebert AD, Barr FA, Aligianis IA, Sidjanin DJ: Loss-of-function
4 mutations in TBC1D20 cause cataracts and male infertility in blind sterile mice and Warburg micro
5 syndrome in humans. *Am J Hum Genet* 2013;93:1001-1014.
- 6 19 Aligianis IA, Johnson CA, Gissen P, Chen D, Hampshire D, Hoffmann K, Maina EN, Morgan NV,
7 Tee L, Morton J, Ainsworth JR, Horn D, Rosser E, Cole TR, Stolte-Dijkstra I, Fieggen K, Clayton-Smith J,
8 Megarbane A, Shield JP, Newbury-Ecob R, Dobyns WB, Graham JM, Jr., Kjaer KW, Warburg M, Bond J,
9 Trembath RC, Harris LW, Takai Y, Mundlos S, Tannahill D, Woods CG, Maher ER: Mutations of the
10 catalytic subunit of RAB3GAP cause Warburg Micro syndrome. *Nat Genet* 2005;37:221-223.
- 11 20 Borck G, Wunram H, Steiert A, Volk AE, Korber F, Roters S, Herkenrath P, Wollnik B, Morris-
12 Rosendahl DJ, Kubisch C: A homozygous RAB3GAP2 mutation causes Warburg Micro syndrome. *Hum*
13 *Genet* 2011;129:45-50.
- 14 21 Dejgaard SY, Murshid A, Erman A, Kizilay O, Verbich D, Lodge R, Dejgaard K, Ly-Hartig TB,
15 Pepperkok R, Simpson JC, Presley JF: Rab18 and Rab43 have key roles in ER-Golgi trafficking. *J Cell Sci*
16 2008;121:2768-2781.
- 17 22 Handley MT, Carpanini SM, Mali GR, Sidjanin DJ, Aligianis IA, Jackson IJ, FitzPatrick DR:
18 Warburg Micro syndrome is caused by RAB18 deficiency or dysregulation. *Open biology*
19 2015;5:150047.
- 20 23 Gerondopoulos A, Bastos RN, Yoshimura S, Anderson R, Carpanini S, Aligianis I, Handley MT,
21 Barr FA: Rab18 and a Rab18 GEF complex are required for normal ER structure. *The Journal of cell*
22 *biology* 2014;205:707-720.
- 23 24 Bora E, Cankaya T, Alpman A, Karaca E, Cogulu O, Tekgul H, Ozkinay F: A new case of Martsolf
24 syndrome. *Genetic counseling* 2007;18:71-75.
- 25 25 Hennekam RC, van de Meeberg AG, van Doorne JM, Dijkstra PF, Bijlsma JB: Martsolf syndrome
26 in a brother and sister: clinical features and pattern of inheritance. *European journal of pediatrics*
27 1988;147:539-543.
- 28 26 Deciphering Developmental Disorders S: Large-scale discovery of novel genetic causes of
29 developmental disorders. *Nature* 2015;519:223-228.
- 30 27 Mir A, Kaufman L, Noor A, Motazacker MM, Jamil T, Azam M, Kahrizi K, Rafiq MA, Weksberg R,
31 Nasr T, Naeem F, Tzschach A, Kuss AW, Ishak GE, Doherty D, Ropers HH, Barkovich AJ, Najmabadi H,
32 Ayub M, Vincent JB: Identification of mutations in TRAPPC9, which encodes the NIK- and IKK-beta-
33 binding protein, in nonsyndromic autosomal-recessive mental retardation. *Am J Hum Genet*
34 2009;85:909-915.
- 35 28 Mochida GH, Mahajnah M, Hill AD, Basel-Vanagaite L, Gleason D, Hill RS, Bodell A, Crosier M,
36 Straussberg R, Walsh CA: A truncating mutation of TRAPPC9 is associated with autosomal-recessive
37 intellectual disability and postnatal microcephaly. *Am J Hum Genet* 2009;85:897-902.
- 38 29 Philippe O, Rio M, Carioux A, Plaza JM, Guigue P, Molinari F, Boddaert N, Bole-Feysot C,
39 Nitschke P, Smahi A, Munnich A, Colleaux L: Combination of linkage mapping and microarray-
40 expression analysis identifies NF-kappaB signaling defect as a cause of autosomal-recessive mental
41 retardation. *Am J Hum Genet* 2009;85:903-908.
- 42 30 Abou Jamra R, Wohlfart S, Zweier M, Uebe S, Priebe L, Ekici A, Giesebrecht S, Abboud A, Al
43 Khateeb MA, Fakher M, Hamdan S, Ismael A, Muhammad S, Nothen MM, Schumacher J, Reis A:
44 Homozygosity mapping in 64 Syrian consanguineous families with non-specific intellectual disability
45 reveals 11 novel loci and high heterogeneity. *Eur J Hum Genet* 2011;19:1161-1166.
- 46 31 Kakar N, Goebel I, Daud S, Nurnberg G, Agha N, Ahmad A, Nurnberg P, Kubisch C, Ahmad J,
47 Borck G: A homozygous splice site mutation in TRAPPC9 causes intellectual disability and
48 microcephaly. *Eur J Med Genet* 2012;55:727-731.
- 49 32 Marangi G, Leuzzi V, Manti F, Lattante S, Orteschi D, Pecile V, Neri G, Zollino M: TRAPPC9-
50 related autosomal recessive intellectual disability: report of a new mutation and clinical phenotype.
51 *Eur J Hum Genet* 2013;21:229-232.
- 52 33 Barrowman J, Bhandari D, Reinisch K, Ferro-Novick S: TRAPP complexes in membrane traffic:
53 converge through a common Rab. *Nature reviews Molecular cell biology* 2010;11:759-763.

- 1 34 Barnekow A, Thyrock A, Kessler D: Chapter 5: rab proteins and their interaction partners.
 2 International review of cell and molecular biology 2009;274:235-274.
- 3 35 Zong M, Satoh A, Yu MK, Siu KY, Ng WY, Chan HC, Tanner JA, Yu S: TRAPPC9 mediates the
 4 interaction between p150 and COPII vesicles at the target membrane. PLoS One 2012;7:e29995.
- 5 36 Milev MP, Grout ME, Saint-Dic D, Cheng YH, Glass IA, Hale CJ, Hanna DS, Dorschner MO,
 6 Prematilake K, Shaag A, Elpeleg O, Sacher M, Doherty D, Edvardson S: Mutations in TRAPPC12 Manifest
 7 in Progressive Childhood Encephalopathy and Golgi Dysfunction. Am J Hum Genet 2017;101:291-299.
- 8 37 Marin-Valencia I, Novarino G, Johansen A, Rosti B, Issa MY, Musaeov D, Bhat G, Scott E, Silhavy
 9 JL, Stanley V, Rosti RO, Gleeson JW, Imam FB, Zaki MS, Gleeson JG: A homozygous founder mutation in
 10 TRAPPC6B associates with a neurodevelopmental disorder characterised by microcephaly, epilepsy
 11 and autistic features. J Med Genet 2018;55:48-54.
- 12 38 Park SY, Yang JS, Schmider AB, Soberman RJ, Hsu VW: Coordinated regulation of bidirectional
 13 COPI transport at the Golgi by CDC42. Nature 2015;521:529-532.
- 14 39 Martinelli S, Krumbach OHF, Pantaleoni F, Coppola S, Amin E, Pannone L, Nouri K, Farina L,
 15 Dvorsky R, Lepri F, Buchholzer M, Konopatzki R, Walsh L, Payne K, Pierpont ME, Vergano SS, Langley
 16 KG, Larsen D, Farwell KD, Tang S, Mroske C, Gallotta I, Di Schiavi E, Della Monica M, Lugli L, Rossi C, Seri
 17 M, Cocchi G, Henderson L, Baskin B, Alders M, Mendoza-Londono R, Dupuis L, Nickerson DA, Chong JX,
 18 University of Washington Center for Mendelian G, Meeks N, Brown K, Causey T, Cho MT, Demuth S,
 19 Digilio MC, Gelb BD, Bamshad MJ, Zenker M, Ahmadian MR, Hennekam RC, Tartaglia M, Mirzaa GM:
 20 Functional Dysregulation of CDC42 Causes Diverse Developmental Phenotypes. Am J Hum Genet 2018
 21 40 Shamseldin HE, Bennett AH, Alfadhel M, Gupta V, Alkuraya FS: GOLGA2, encoding a master
 22 regulator of golgi apparatus, is mutated in a patient with a neuromuscular disorder. Hum Genet
 23 2016;135:245-251.
- 24 41 Nakamura N: Emerging new roles of GM130, a cis-Golgi matrix protein, in higher order cell
 25 functions. Journal of pharmacological sciences 2010;112:255-264.
- 26 42 Short B, Preisinger C, Korner R, Kopajtich R, Byron O, Barr FA: A GRASP55-rab2 effector
 27 complex linking Golgi structure to membrane traffic. The Journal of cell biology 2001;155:877-883.
- 28 43 Valsdottir R, Hashimoto H, Ashman K, Koda T, Storrie B, Nilsson T: Identification of rabaptin-5,
 29 rabex-5, and GM130 as putative effectors of rab33b, a regulator of retrograde traffic between the
 30 Golgi apparatus and ER. FEBS Lett 2001;508:201-209.
- 31 44 Alwadei AH, Benini R, Mahmoud A, Alasmari A, Kamsteeg EJ, Alfadhel M: Loss-of-function
 32 mutation in RUSC2 causes intellectual disability and secondary microcephaly. Developmental medicine
 33 and child neurology 2016;58:1317-1322.
- 34 45 Bayer M, Fischer J, Kremerskothen J, Ossendorf E, Matanis T, Konczal M, Weide T, Barnekow A:
 35 Identification and characterization of Iporin as a novel interaction partner for rab1. BMC cell biology
 36 2005;6:15.
- 37 46 Wang H, Falk MJ, Wensel C, Traboulsi EI: Cohen Syndrome; in Pagon RA, Adam MP, Ardinger
 38 HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K (eds):
 39 GeneReviews(R). Seattle (WA), 1993
- 40 47 Falk MJ, Feiler HS, Neilson DE, Maxwell K, Lee JV, Segall SK, Robin NH, Wilhelmsen KC, Traskelin
 41 AL, Kolehmainen J, Lehesjoki AE, Wiznitzer M, Warman ML: Cohen syndrome in the Ohio Amish. Am J
 42 Med Genet A 2004;128A:23-28.
- 43 48 Kivitie-Kallio S, Autti T, Salonen O, Norio R: MRI of the brain in the Cohen syndrome: a
 44 relatively large corpus callosum in patients with mental retardation and microcephaly. Neuropediatrics
 45 1998;29:298-301.
- 46 49 Seifert W, Kuhnisch J, Maritzen T, Horn D, Haucke V, Hennies HC: Cohen syndrome-associated
 47 protein, COH1, is a novel, giant Golgi matrix protein required for Golgi integrity. J Biol Chem
 48 2011;286:37665-37675.
- 49 50 Seifert W, Kuhnisch J, Maritzen T, Lommatzsch S, Hennies HC, Bachmann S, Horn D, Haucke V:
 50 Cohen syndrome-associated protein COH1 physically and functionally interacts with the small GTPase
 51 RAB6 at the Golgi complex and directs neurite outgrowth. J Biol Chem 2015;290:3349-3358.

- 1 51 Ben-Zeev B, Hoffman C, Lev D, Watemala N, Malinger G, Brand N, Lerman-Sagie T:
2 Progressive cerebellocerebral atrophy: a new syndrome with microcephaly, mental retardation, and
3 spastic quadriplegia. *J Med Genet* 2003;40:e96.
- 4 52 Feinstein M, Flusser H, Lerman-Sagie T, Ben-Zeev B, Lev D, Agamy O, Cohen I, Kadir R, Sivan S,
5 Leshinsky-Silver E, Markus B, Birk OS: VPS53 mutations cause progressive cerebello-cerebral atrophy
6 type 2 (PCCA2). *J Med Genet* 2014;51:303-308.
- 7 53 Bonifacino JS, Hierro A: Transport according to GARP: receiving retrograde cargo at the trans-
8 Golgi network. *Trends in cell biology* 2011;21:159-167.
- 9 54 Schindler C, Chen Y, Pu J, Guo X, Bonifacino JS: EARP is a multisubunit tethering complex
10 involved in endocytic recycling. *Nat Cell Biol* 2015;17:639-650.
- 11 55 Liewen H, Meinhold-Heerlein I, Oliveira V, Schwarzenbacher R, Luo G, Wadle A, Jung M,
12 Pfreundschuh M, Stenner-Liewen F: Characterization of the human GARP (Golgi associated retrograde
13 protein) complex. *Experimental cell research* 2005;306:24-34.
- 14 56 Ivanova EL, Mau-Them FT, Riazuddin S, Kahrizi K, Laugel V, Schaefer E, de Saint Martin A,
15 Runge K, Iqbal Z, Spitz MA, Laura M, Drouot N, Gerard B, Deleuze JF, de Brouwer APM, Razzaq A,
16 Dollfus H, Assir MZ, Nitchke P, Hinckelmann MV, Ropers H, Riazuddin S, Najmabadi H, van Bokhoven H,
17 Chelly J: Homozygous Truncating Variants in TBC1D23 Cause Pontocerebellar Hypoplasia and Alter
18 Cortical Development. *Am J Hum Genet* 2017;101:428-440.
- 19 57 Marin-Valencia I, Gerondopoulos A, Zaki MS, Ben-Omran T, Almureikhi M, Demir E, Guemez-
20 Gamboa A, Gregor A, Issa MY, Appelhof B, Roosing S, Musaev D, Rosti B, Wirth S, Stanley V, Baas F,
21 Barr FA, Gleeson JG: Homozygous Mutations in TBC1D23 Lead to a Non-degenerative Form of
22 Pontocerebellar Hypoplasia. *Am J Hum Genet* 2017;101:441-450.
- 23 58 Shin JH, Gillingham AK, Begum F, Chadwick J, Munro S: TBC1D23 is a bridging factor for
24 endosomal vesicle capture by golgins at the trans-Golgi. *Nat Cell Biol* 2017;19:1424-1432.
- 25 59 Banne E, Atawneh O, Henneke M, Brockmann K, Gartner J, Elpeleg O, Edvardson S: West
26 syndrome, microcephaly, grey matter heterotopia and hypoplasia of corpus callosum due to a novel
27 ARFGEF2 mutation. *J Med Genet* 2013;50:772-775.
- 28 60 de Wit MC, de Coo IF, Halley DJ, Lequin MH, Mancini GM: Movement disorder and neuronal
29 migration disorder due to ARFGEF2 mutation. *Neurogenetics* 2009;10:333-336.
- 30 61 Tanyalcin I, Verhelst H, Halley DJ, Vanderhasselt T, Villard L, Goizet C, Lissens W, Mancini GM,
31 Jansen AC: Elaborating the phenotypic spectrum associated with mutations in ARFGEF2: case study
32 and literature review. *European journal of paediatric neurology : EJPN : official journal of the European
33 Paediatric Neurology Society* 2013;17:666-670.
- 34 62 Sheen VL, Ganesh VS, Topcu M, Sebire G, Bodell A, Hill RS, Grant PE, Shugart YY, Imitola J,
35 Khoury SJ, Guerrini R, Walsh CA: Mutations in ARFGEF2 implicate vesicle trafficking in neural
36 progenitor proliferation and migration in the human cerebral cortex. *Nat Genet* 2004;36:69-76.
- 37 63 Bui QT, Golinelli-Cohen MP, Jackson CL: Large Arf1 guanine nucleotide exchange factors:
38 evolution, domain structure, and roles in membrane trafficking and human disease. *Molecular genetics
39 and genomics : MGG* 2009;282:329-350.
- 40 64 Kawauchi T, Sekine K, Shikanai M, Chihama K, Tomita K, Kubo K, Nakajima K, Nabeshima Y,
41 Hoshino M: Rab GTPases-dependent endocytic pathways regulate neuronal migration and maturation
42 through N-cadherin trafficking. *Neuron* 2010;67:588-602.
- 43 65 Nieuwenhuis B, Eva R: ARF6 and Rab11 as intrinsic regulators of axon regeneration. *Small
44 GTPases* 2018:1-10.
- 45 66 Guardia CM, De Pace R, Mattera R, Bonifacino JS: Neuronal functions of adaptor complexes
46 involved in protein sorting. *Curr Opin Neurobiol* 2018;51:103-110.
- 47 67 Martinelli D, Travaglini L, Drouin CA, Ceballos-Picot I, Rizza T, Bertini E, Carozzo R, Petrini S, de
48 Lonlay P, El Hachem M, Hubert L, Montpetit A, Torre G, Dionisi-Vici C: MEDNIK syndrome: a novel
49 defect of copper metabolism treatable by zinc acetate therapy. *Brain* 2013;136:872-881.
- 50 68 Montpetit A, Cote S, Brustein E, Drouin CA, Lapointe L, Boudreau M, Meloche C, Drouin R,
51 Hudson TJ, Drapeau P, Cossette P: Disruption of AP1S1, causing a novel neurocutaneous syndrome,
52 perturbs development of the skin and spinal cord. *PLoS Genet* 2008;4:e1000296.

- 1 69 Saba TG, Montpetit A, Verner A, Rioux P, Hudson TJ, Drouin R, Drouin CA: An atypical form of
2 erythrokeratoderma variabilis maps to chromosome 7q22. *Hum Genet* 2005;116:167-171.
- 3 70 Cacciagli P, Desvignes JP, Girard N, Delepine M, Zelenika D, Lathrop M, Levy N, Ledbetter DH,
4 Dobyns WB, Villard L: AP1S2 is mutated in X-linked Dandy-Walker malformation with intellectual
5 disability, basal ganglia disease and seizures (Pettigrew syndrome). *Eur J Hum Genet* 2014;22:363-368.
- 6 71 Pettigrew AL, Jackson LG, Ledbetter DH: New X-linked mental retardation disorder with Dandy-
7 Walker malformation, basal ganglia disease, and seizures. *Am J Med Genet* 1991;38:200-207.
- 8 72 Freeze HH, Ng BG: Golgi glycosylation and human inherited diseases. *Cold Spring Harbor*
9 *perspectives in biology* 2011;3:a005371.
- 10 73 Climer LK, Dobretsov M, Lupashin V: Defects in the COG complex and COG-related trafficking
11 regulators affect neuronal Golgi function. *Frontiers in neuroscience* 2015;9:405.
- 12 74 Shestakova A, Zolov S, Lupashin V: COG complex-mediated recycling of Golgi
13 glycosyltransferases is essential for normal protein glycosylation. *Traffic* 2006;7:191-204.
- 14 75 Foulquier F, Ungar D, Reynders E, Zeevaert R, Mills P, Garcia-Silva MT, Briones P, Winchester B,
15 Morelle W, Krieger M, Annaert W, Matthijs G: A new inborn error of glycosylation due to a Cog8
16 deficiency reveals a critical role for the Cog1-Cog8 interaction in COG complex formation. *Hum Mol*
17 *Genet* 2007;16:717-730.
- 18 76 Foulquier F, Vasile E, Schollen E, Callewaert N, Raemaekers T, Quelhas D, Jaeken J, Mills P,
19 Winchester B, Krieger M, Annaert W, Matthijs G: Conserved oligomeric Golgi complex subunit 1
20 deficiency reveals a previously uncharacterized congenital disorder of glycosylation type II. *Proc Natl*
21 *Acad Sci U S A* 2006;103:3764-3769.
- 22 77 Kodera H, Ando N, Yuasa I, Wada Y, Tsurusaki Y, Nakashima M, Miyake N, Saitoh S, Matsumoto
23 N, Saitsu H: Mutations in COG2 encoding a subunit of the conserved oligomeric golgi complex cause a
24 congenital disorder of glycosylation. *Clinical genetics* 2015;87:455-460.
- 25 78 Morava E, Zeevaert R, Korsch E, Huijben K, Wopereis S, Matthijs G, Keymolen K, Lefeber DJ, De
26 Meirleir L, Wevers RA: A common mutation in the COG7 gene with a consistent phenotype including
27 microcephaly, adducted thumbs, growth retardation, VSD and episodes of hyperthermia. *Eur J Hum*
28 *Genet* 2007;15:638-645.
- 29 79 Reynders E, Foulquier F, Leao Teles E, Quelhas D, Morelle W, Rabouille C, Annaert W, Matthijs
30 G: Golgi function and dysfunction in the first COG4-deficient CDG type II patient. *Hum Mol Genet*
31 2009;18:3244-3256.
- 32 80 Rymen D, Keldermans L, Race V, Regal L, Deconinck N, Dionisi-Vici C, Fung CW, Sturiale L,
33 Rosnoblet C, Foulquier F, Matthijs G, Jaeken J: COG5-CDG: expanding the clinical spectrum. *Orphanet*
34 *journal of rare diseases* 2012;7:94.
- 35 81 Yang A, Cho SY, Jang JH, Kim J, Kim SZ, Lee BH, Yoo HW, Jin DK: Further delineation of COG8-
36 CDG: A case with novel compound heterozygous mutations diagnosed by targeted exome sequencing.
37 *Clinica chimica acta; international journal of clinical chemistry* 2017;471:191-195.
- 38 82 Huybrechts S, De Laet C, Bontems P, Rooze S, Souayah H, Sznajer Y, Sturiale L, Garozzo D,
39 Matthijs G, Ferster A, Jaeken J, Goyens P: Deficiency of Subunit 6 of the Conserved Oligomeric Golgi
40 Complex (COG6-CDG): Second Patient, Different Phenotype. *JIMD reports* 2012;4:103-108.
- 41 83 Rymen D, Winter J, Van Hasselt PM, Jaeken J, Kasapkara C, Gokcay G, Haijes H, Goyens P,
42 Tokatli A, Thiel C, Bartsch O, Hecht J, Krawitz P, Prinsen HC, Mildemberger E, Matthijs G, Kornak U: Key
43 features and clinical variability of COG6-CDG. *Mol Genet Metab* 2015;116:163-170.
- 44 84 Edvardson S, Ashikov A, Jalas C, Sturiale L, Shaag A, Fedick A, Treff NR, Garozzo D, Gerardy-
45 Schahn R, Elpeleg O: Mutations in SLC35A3 cause autism spectrum disorder, epilepsy and
46 arthrogyriposis. *J Med Genet* 2013;50:733-739.
- 47 85 Frydman M, Etzioni A, Eidlitz-Markus T, Avidor I, Varsano I, Shechter Y, Orlin JB, Gershoni-
48 Baruch R: Rambam-Hasharon syndrome of psychomotor retardation, short stature, defective
49 neutrophil motility, and Bombay phenotype. *Am J Med Genet* 1992;44:297-302.
- 50 86 Dulary E, Potelle S, Legrand D, Foulquier F: TMEM165 deficiencies in Congenital Disorders of
51 Glycosylation type II (CDG-II): Clues and evidences for roles of the protein in Golgi functions and ion
52 homeostasis. *Tissue & cell* 2017;49:150-156.

- 1 87 Foulquier F, Amyere M, Jaeken J, Zeevaert R, Schollen E, Race V, Bammens R, Morelle W,
2 Rosnoblet C, Legrand D, Demaegd D, Buist N, Cheillan D, Guffon N, Morsomme P, Annaert W, Freeze
3 HH, Van Schaftingen E, Vikkula M, Matthijs G: TMEM165 deficiency causes a congenital disorder of
4 glycosylation. *Am J Hum Genet* 2012;91:15-26.
- 5 88 Nicholas AK, Khurshid M, Desir J, Carvalho OP, Cox JJ, Thornton G, Kausar R, Ansar M, Ahmad
6 W, Verloes A, Passemard S, Misson JP, Lindsay S, Gergely F, Dobyns WB, Roberts E, Abramowicz M,
7 Woods CG: WDR62 is associated with the spindle pole and is mutated in human microcephaly. *Nat*
8 *Genet* 2010;42:1010-1014.
- 9 89 Yu TW, Mochida GH, Tischfield DJ, Sgaier SK, Flores-Sarnat L, Sergi CM, Topcu M, McDonald
10 MT, Barry BJ, Felie JM, Sunu C, Dobyns WB, Folkert RD, Barkovich AJ, Walsh CA: Mutations in WDR62,
11 encoding a centrosome-associated protein, cause microcephaly with simplified gyri and abnormal
12 cortical architecture. *Nat Genet* 2010;42:1015-1020.
- 13 90 Bond J, Roberts E, Springell K, Lizarraga SB, Scott S, Higgins J, Hampshire DJ, Morrison EE, Leal
14 GF, Silva EO, Costa SM, Baralle D, Raponi M, Karbani G, Rashid Y, Jafri H, Bennett C, Corry P, Walsh CA,
15 Woods CG: A centrosomal mechanism involving CDK5RAP2 and CENPJ controls brain size. *Nat Genet*
16 2005;37:353-355.
- 17 91 Buchman JJ, Tseng HC, Zhou Y, Frank CL, Xie Z, Tsai LH: Cdk5rap2 interacts with pericentrin to
18 maintain the neural progenitor pool in the developing neocortex. *Neuron* 2010;66:386-402.
- 19 92 Lizarraga SB, Margossian SP, Harris MH, Campagna DR, Han AP, Blevins S, Mudbhary R, Barker
20 JE, Walsh CA, Fleming MD: Cdk5rap2 regulates centrosome function and chromosome segregation in
21 neuronal progenitors. *Development* 2010;137:1907-1917.
- 22 93 Wang Z, Wu T, Shi L, Zhang L, Zheng W, Qu JY, Niu R, Qi RZ: Conserved motif of CDK5RAP2
23 mediates its localization to centrosomes and the Golgi complex. *J Biol Chem* 2010;285:22658-22665.
- 24 94 Wu J, de Heus C, Liu Q, Bouchet BP, Noordstra I, Jiang K, Hua S, Martin M, Yang C, Grigoriev I,
25 Katrukha EA, Altelaar AFM, Hoogenraad CC, Qi RZ, Klumperman J, Akhmanova A: Molecular Pathway
26 of Microtubule Organization at the Golgi Apparatus. *Dev Cell* 2016;39:44-60.
- 27 95 Harding BN, Moccia A, Drunat S, Soukariéh O, Tubeuf H, Chitty LS, Verloes A, Gressens P, El
28 Ghouzzi V, Joriot S, Di Cunto F, Martins A, Passemard S, Bielas SL: Mutations in Citron Kinase Cause
29 Recessive Microlissencephaly with Multinucleated Neurons. *Am J Hum Genet* 2016;99:511-520.
- 30 96 Li H, Bielas SL, Zaki MS, Ismail S, Farfara D, Um K, Rosti RO, Scott EC, Tu S, Chi NC, Gabriel S,
31 Erson-Omay EZ, Ercan-Sencicek AG, Yasuno K, Caglayan AO, Kaymakcalan H, Ekici B, Bilguvar K, Gunel
32 M, Gleeson JG: Biallelic Mutations in Citron Kinase Link Mitotic Cytokinesis to Human Primary
33 Microcephaly. *Am J Hum Genet* 2016;99:501-510.
- 34 97 D'Avino PP: Citron kinase - renaissance of a neglected mitotic kinase. *J Cell Sci* 2017;130:1701-
35 1708.
- 36 98 Di Cunto F, Imarisio S, Hirsch E, Broccoli V, Bulfone A, Migheli A, Atzori C, Turco E, Triolo R,
37 Dotto GP, Silengo L, Altruda F: Defective neurogenesis in citron kinase knockout mice by altered
38 cytokinesis and massive apoptosis. *Neuron* 2000;28:115-127.
- 39 99 Camera P, da Silva JS, Griffiths G, Giuffrida MG, Ferrara L, Schubert V, Imarisio S, Silengo L,
40 Dotti CG, Di Cunto F: Citron-N is a neuronal Rho-associated protein involved in Golgi organization
41 through actin cytoskeleton regulation. *Nat Cell Biol* 2003;5:1071-1078.
- 42 100 Camera P, Schubert V, Pellegrino M, Berto G, Vercelli A, Muzzi P, Hirsch E, Altruda F, Dotti CG,
43 Di Cunto F: The RhoA-associated protein Citron-N controls dendritic spine maintenance by interacting
44 with spine-associated Golgi compartments. *EMBO reports* 2008;9:384-392.
- 45 101 Bogershausen N, Shahrzad N, Chong JX, von Kleist-Retzow JC, Stanga D, Li Y, Bernier FP, Loucks
46 CM, Wirth R, Puffenberger EG, Hegele RA, Schreml J, Lapointe G, Keupp K, Brett CL, Anderson R, Hahn
47 A, Innes AM, Suchowersky O, Mets MB, Nurnberg G, McLeod DR, Thiele H, Waggoner D, Altmuller J,
48 Boycott KM, Schoser B, Nurnberg P, Ober C, Heller R, Parboosingh JS, Wollnik B, Sacher M, Lamont RE:
49 Recessive TRAPPC11 mutations cause a disease spectrum of limb girdle muscular dystrophy and
50 myopathy with movement disorder and intellectual disability. *Am J Hum Genet* 2013;93:181-190.
- 51 102 Fee DB, Harmelink M, Monrad P, Pyzik E: Siblings With Mutations in TRAPPC11 Presenting With
52 Limb-Girdle Muscular Dystrophy 2S. *Journal of clinical neuromuscular disease* 2017;19:27-30.

- 1 103 Izumi K, Brett M, Nishi E, Drunat S, Tan ES, Fujiki K, Lebon S, Cham B, Masuda K, Arakawa M,
2 Jacquinet A, Yamazumi Y, Chen ST, Verloes A, Okada Y, Katou Y, Nakamura T, Akiyama T, Gressens P,
3 Foo R, Passemard S, Tan EC, El Ghouzzi V, Shirahige K: ARCN1 Mutations Cause a Recognizable
4 Craniofacial Syndrome Due to COPI-Mediated Transport Defects. *Am J Hum Genet* 2016;99:451-459.
- 5 104 DiStasio A, Driver A, Sund K, Donlin M, Muraleedharan RM, Pooya S, Kline-Fath B, Kaufman
6 KM, Prows CA, Schorry E, Dasgupta B, Stottmann RW: Copb2 is essential for embryogenesis and
7 hypomorphic mutations cause human microcephaly. *Hum Mol Genet* 2017;26:4836-4848.
- 8 105 Nahorski MS, Asai M, Wakeling E, Parker A, Asai N, Canham N, Holder SE, Chen YC, Dyer J,
9 Brady AF, Takahashi M, Woods CG: CCDC88A mutations cause PEHO-like syndrome in humans and
10 mouse. *Brain* 2016;139:1036-1044.
- 11 106 Kim JY, Duan X, Liu CY, Jang MH, Guo JU, Pow-anpongkul N, Kang E, Song H, Ming GL: DISC1
12 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through
13 KIAA1212. *Neuron* 2009;63:761-773.
- 14 107 Fink JK: Hereditary spastic paraplegia: clinical principles and genetic advances. *Seminars in
15 neurology* 2014;34:293-305.
- 16 108 Abou Jamra R, Philippe O, Raas-Rothschild A, Eck SH, Graf E, Buchert R, Borck G, Ekici A,
17 Brockschmidt FF, Nothen MM, Munnich A, Strom TM, Reis A, Colleaux L: Adaptor protein complex 4
18 deficiency causes severe autosomal-recessive intellectual disability, progressive spastic paraplegia, shy
19 character, and short stature. *Am J Hum Genet* 2011;88:788-795.
- 20 109 De Pace R, Skirzewski M, Damme M, Mattera R, Mercurio J, Foster AM, Cuitino L, Jarnik M,
21 Hoffmann V, Morris HD, Han TU, Mancini GMS, Buonanno A, Bonifacino JS: Altered distribution of
22 ATG9A and accumulation of axonal aggregates in neurons from a mouse model of AP-4 deficiency
23 syndrome. *PLoS Genet* 2018;14:e1007363.
- 24 110 Moreno-De-Luca A, Helmers SL, Mao H, Burns TG, Melton AM, Schmidt KR, Fernhoff PM,
25 Ledbetter DH, Martin CL: Adaptor protein complex-4 (AP-4) deficiency causes a novel autosomal
26 recessive cerebral palsy syndrome with microcephaly and intellectual disability. *J Med Genet*
27 2011;48:141-144.
- 28 111 Verkerk AJ, Schot R, Dumeé B, Schellekens K, Swagemakers S, Bertoli-Avella AM, Lequin MH,
29 Dudink J, Govaert P, van Zwol AL, Hirst J, Wessels MW, Catsman-Berrevoets C, Verheijen FW, de Graaff
30 E, de Coo IF, Kros JM, Willemsen R, Willems PJ, van der Spek PJ, Mancini GM: Mutation in the AP4M1
31 gene provides a model for neuroaxonal injury in cerebral palsy. *Am J Hum Genet* 2009;85:40-52.
- 32 112 Kotzot D, Richter K, Gierth-Fiebig K: Oculocutaneous albinism, immunodeficiency,
33 hematological disorders, and minor anomalies: a new autosomal recessive syndrome? *Am J Med
34 Genet* 1994;50:224-227.
- 35 113 Christianson AL, Stevenson RE, van der Meyden CH, Pelsler J, Theron FW, van Rensburg PL,
36 Chandler M, Schwartz CE: X linked severe mental retardation, craniofacial dysmorphology, epilepsy,
37 ophthalmoplegia, and cerebellar atrophy in a large South African kindred is localised to Xq24-q27. *J
38 Med Genet* 1999;36:759-766.
- 39 114 Gilfillan GD, Selmer KK, Roxrud I, Smith R, Kyllerman M, Eiklid K, Kroken M, Mattingsdal M,
40 Egeland T, Stenmark H, Sjöholm H, Server A, Samuelsson L, Christianson A, Tarpey P, Whibley A,
41 Stratton MR, Futreal PA, Teague J, Edkins S, Gecz J, Turner G, Raymond FL, Schwartz C, Stevenson RE,
42 Undlien DE, Stromme P: SLC9A6 mutations cause X-linked mental retardation, microcephaly, epilepsy,
43 and ataxia, a phenotype mimicking Angelman syndrome. *Am J Hum Genet* 2008;82:1003-1010.
- 44 115 Schroer RJ, Holden KR, Tarpey PS, Matheus MG, Griesemer DA, Friez MJ, Fan JZ, Simensen RJ,
45 Stromme P, Stevenson RE, Stratton MR, Schwartz CE: Natural history of Christianson syndrome. *Am J
46 Med Genet A* 2010;152A:2775-2783.
- 47 116 Anazi S, Maddirevula S, Faqeih E, Alsedairy H, Alzahrani F, Shamseldin HE, Patel N, Hashem M,
48 Ibrahim N, Abdulwahab F, Ewida N, Alsaif HS, Al Sharif H, Alamoudi W, Kentab A, Bashiri FA, Alnaser M,
49 AlWadei AH, Alfadhel M, Eyaid W, Hashem A, Al Asmari A, Saleh MM, AlSaman A, Alhasan KA,
50 Alsughayir M, Al Shammari M, Mahmoud A, Al-Hassnan ZN, Al-Husain M, Osama Khalil R, Abd El
51 Meguid N, Masri A, Ali R, Ben-Omran T, El Fishway P, Hashish A, Ercan Sencicek A, State M, Alazami
52 AM, Salih MA, Altassan N, Arold ST, Abouelhoda M, Wakil SM, Monies D, Shaheen R, Alkuraya FS:

- 1 Clinical genomics expands the morbid genome of intellectual disability and offers a high diagnostic
2 yield. *Molecular psychiatry* 2017;22:615-624.
- 3 117 Han C, Alkhater R, Froukh T, Minassian AG, Galati M, Liu RH, Fotouhi M, Sommerfeld J, Alfrook
4 AJ, Marshall C, Walker S, Bauer P, Scherer SW, Riess O, Buchert R, Minassian BA, McPherson PS:
5 Epileptic Encephalopathy Caused by Mutations in the Guanine Nucleotide Exchange Factor DENND5A.
6 *Am J Hum Genet* 2016;99:1359-1367.
- 7 118 Yoshimura S, Gerondopoulos A, Linford A, Rigden DJ, Barr FA: Family-wide characterization of
8 the DENN domain Rab GDP-GTP exchange factors. *The Journal of cell biology* 2010;191:367-381.
- 9 119 Giannandrea M, Bianchi V, Mignogna ML, Sirri A, Carrabino S, D'Elia E, Vecellio M, Russo S,
10 Cogliati F, Larizza L, Ropers HH, Tzschach A, Kalscheuer V, Oehl-Jaschkowitz B, Skinner C, Schwartz CE,
11 Gecz J, Van Esch H, Raynaud M, Chelly J, de Brouwer AP, Toniolo D, D'Adamo P: Mutations in the small
12 GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy,
13 and macrocephaly. *Am J Hum Genet* 2010;86:185-195.
- 14 120 Woodbury-Smith M, Deneault E, Yuen RKC, Walker S, Zarrei M, Pellecchia G, Howe JL, Hoang
15 N, Uddin M, Marshall CR, Chrysler C, Thompson A, Szatmari P, Scherer SW: Mutations in RAB39B in
16 individuals with intellectual disability, autism spectrum disorder, and macrocephaly. *Molecular autism*
17 2017;8:59.
- 18 121 Laxova R, Brown ES, Hogan K, Hecox K, Opitz JM: An X-linked recessive basal ganglia disorder
19 with mental retardation. *Am J Med Genet* 1985;21:681-689.
- 20 122 Wilson GR, Sim JC, McLean C, Giannandrea M, Galea CA, Riseley JR, Stephenson SE, Fitzpatrick
21 E, Haas SA, Pope K, Hogan KJ, Gregg RG, Bromhead CJ, Wargowski DS, Lawrence CH, James PA,
22 Churchyard A, Gao Y, Phelan DG, Gillies G, Salce N, Stanford L, Marsh AP, Mignogna ML, Hayflick SJ,
23 Leventer RJ, Delatycki MB, Mellick GD, Kalscheuer VM, D'Adamo P, Bahlo M, Amor DJ, Lockhart PJ:
24 Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with
25 alpha-synuclein pathology. *Am J Hum Genet* 2014;95:729-735.
- 26 123 Rosa JL, Casaroli-Marano RP, Buckler AJ, Vilaro S, Barbacid M: p619, a giant protein related to
27 the chromosome condensation regulator RCC1, stimulates guanine nucleotide exchange on ARF1 and
28 Rab proteins. *EMBO J* 1996;15:4262-4273.
- 29 124 Aggarwal S, Bhowmik AD, Ramprasad VL, Murugan S, Dalal A: A splice site mutation in HERC1
30 leads to syndromic intellectual disability with macrocephaly and facial dysmorphism: Further
31 delineation of the phenotypic spectrum. *Am J Med Genet A* 2016;170:1868-1873.
- 32 125 Nguyen LS, Schneider T, Rio M, Moutton S, Siquier-Pernet K, Verny F, Boddaert N, Desguerre I,
33 Munich A, Rosa JL, Cormier-Daire V, Colleaux L: A nonsense variant in HERC1 is associated with
34 intellectual disability, megalencephaly, thick corpus callosum and cerebellar atrophy. *Eur J Hum Genet*
35 2016;24:455-458.
- 36 126 Ortega-Recalde O, Beltran OI, Galvez JM, Palma-Montero A, Restrepo CM, Mateus HE, Laissue
37 P: Biallelic HERC1 mutations in a syndromic form of overgrowth and intellectual disability. *Clinical*
38 *genetics* 2015;88:e1-3.
- 39 127 Reijnders MRF, Anzor NM, Kousi M, Yue WW, Tan PL, Clarkson K, Clayton-Smith J, Corning K,
40 Jones JR, Lam WWK, Mancini GMS, Marcelis C, Mohammed S, Pfundt R, Roifman M, Cohn R, Chitayat
41 D, Deciphering Developmental Disorders S, Millard TH, Katsanis N, Brunner HG, Banka S: RAC1
42 Missense Mutations in Developmental Disorders with Diverse Phenotypes. *Am J Hum Genet*
43 2017;101:466-477.
- 44 128 Bristow JM, Sellers MH, Majumdar D, Anderson B, Hu L, Webb DJ: The Rho-family GEF Asef2
45 activates Rac to modulate adhesion and actin dynamics and thereby regulate cell migration. *J Cell Sci*
46 2009;122:4535-4546.
- 47 129 Evans JC, Robinson CM, Shi M, Webb DJ: The guanine nucleotide exchange factor (GEF) Asef2
48 promotes dendritic spine formation via Rac activation and spinophilin-dependent targeting. *J Biol*
49 *Chem* 2015;290:10295-10308.
- 50 130 Harripaul R, Vasli N, Mikhailov A, Rafiq MA, Mittal K, Windpassinger C, Sheikh TI, Noor A,
51 Mahmood H, Downey S, Johnson M, Vleuten K, Bell L, Ilyas M, Khan FS, Khan V, Moradi M, Ayaz M,
52 Naeem F, Heidari A, Ahmed I, Ghadami S, Agha Z, Zeinali S, Qamar R, Mozhdehipanah H, John P, Mir A,
53 Ansar M, French L, Ayub M, Vincent JB: Mapping autosomal recessive intellectual disability: combined

- 1 microarray and exome sequencing identifies 26 novel candidate genes in 192 consanguineous families.
2 Molecular psychiatry 2018;23:973-984.
- 3 131 Bi W, Glass IA, Muzny DM, Gibbs RA, Eng CM, Yang Y, Sun A: Whole exome sequencing
4 identifies the first STRADA point mutation in a patient with polyhydramnios, megalencephaly, and
5 symptomatic epilepsy syndrome (PMSE). Am J Med Genet A 2016;170:2181-2185.
- 6 132 Puffenberger EG, Strauss KA, Ramsey KE, Craig DW, Stephan DA, Robinson DL, Hendrickson CL,
7 Gottlieb S, Ramsay DA, Siu VM, Heuer GG, Crino PB, Morton DH: Polyhydramnios, megalencephaly and
8 symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5. Brain 2007;130:1929-1941.
- 9 133 Rao S, Kirschen GW, Szczurkowska J, Di Antonio A, Wang J, Ge S, Shelly M: Repositioning of
10 Somatic Golgi Apparatus Is Essential for the Dendritic Establishment of Adult-Born Hippocampal
11 Neurons. J Neurosci 2018;38:631-647.
- 12 134 Bienvenu T, des Portes V, Saint Martin A, McDonnell N, Billuart P, Carrie A, Vinet MC, Couvert P,
13 Toniolo D, Ropers HH, Moraine C, van Bokhoven H, Fryns JP, Kahn A, Beldjord C, Chelly J: Non-specific
14 X-linked semidominant mental retardation by mutations in a Rab GDP-dissociation inhibitor. Hum Mol
15 Genet 1998;7:1311-1315.
- 16 135 D'Adamo P, Menegon A, Lo Nigro C, Grasso M, Gulisano M, Tamanini F, Bienvenu T, Gedeon
17 AK, Oostra B, Wu SK, Tandon A, Valtorta F, Balch WE, Chelly J, Toniolo D: Mutations in GDI1 are
18 responsible for X-linked non-specific mental retardation. Nat Genet 1998;19:134-139.
- 19 136 More L, Kunnecke B, Yekhleif L, Bruns A, Marte A, Fedele E, Bianchi V, Taverna S, Gatti S,
20 D'Adamo P: Altered fronto-striatal functions in the Gdi1-null mouse model of X-linked Intellectual
21 Disability. Neuroscience 2017;344:346-359.
- 22 137 Zhang J, Neal J, Lian G, Hu J, Lu J, Sheen V: Filamin A regulates neuronal migration through
23 brefeldin A-inhibited guanine exchange factor 2-dependent Arf1 activation. J Neurosci 2013;33:15735-
24 15746.
- 25 138 Chen MH, Walsh CA: FLNA-Related Periventricular Nodular Heterotopia; in Adam MP, Ardinger
26 HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (eds): GeneReviews((R)). Seattle (WA),
27 1993
- 28 139 Schuurs-Hoeijmakers JH, Oh EC, Vissers LE, Swinkels ME, Gilissen C, Willemsen MA, Holvoet M,
29 Steehouwer M, Veltman JA, de Vries BB, van Bokhoven H, de Brouwer AP, Katsanis N, Devriendt K,
30 Brunner HG: Recurrent de novo mutations in PACS1 cause defective cranial-neural-crest migration and
31 define a recognizable intellectual-disability syndrome. Am J Hum Genet 2012;91:1122-1127.
- 32 140 Schmidt WM, Rutledge SL, Schule R, Mayerhofer B, Zuchner S, Boltshauser E, Bittner RE:
33 Disruptive SCYL1 Mutations Underlie a Syndrome Characterized by Recurrent Episodes of Liver Failure,
34 Peripheral Neuropathy, Cerebellar Atrophy, and Ataxia. Am J Hum Genet 2015;97:855-861.
- 35 141 Martinez-Carrera LA, Wirth B: Dominant spinal muscular atrophy is caused by mutations in
36 BICD2, an important golgin protein. Frontiers in neuroscience 2015;9:401.
- 37 142 Oates EC, Rossor AM, Hafezparast M, Gonzalez M, Speziani F, MacArthur DG, Lek M, Cottenie
38 E, Scoto M, Foley AR, Hurles M, Houlden H, Greensmith L, Auer-Grumbach M, Pieber TR, Strom TM,
39 Schule R, Herrmann DN, Sowden JE, Acsadi G, Menezes MP, Clarke NF, Zuchner S, Uk10K, Muntoni F,
40 North KN, Reilly MM: Mutations in BICD2 cause dominant congenital spinal muscular atrophy and
41 hereditary spastic paraplegia. Am J Hum Genet 2013;92:965-973.
- 42 143 Peeters K, Litvinenko I, Asselbergh B, Almeida-Souza L, Chamova T, Geuens T, Ydens E, Zimon
43 M, Irobi J, De Vriendt E, De Winter V, Ooms T, Timmerman V, Tournev I, Jordanova A: Molecular
44 defects in the motor adaptor BICD2 cause proximal spinal muscular atrophy with autosomal-dominant
45 inheritance. Am J Hum Genet 2013;92:955-964.
- 46 144 Lee PL, Ohlson MB, Pfeffer SR: Rab6 regulation of the kinesin family KIF1C motor domain
47 contributes to Golgi tethering. eLife 2015;4
- 48 145 Bouslam N, Bouhouche A, Benomar A, Hanein S, Klebe S, Azzedine H, Di Giandomenico S,
49 Boland-Auge A, Santorelli FM, Durr A, Brice A, Yahyaoui M, Stevanin G: A novel locus for autosomal
50 recessive spastic ataxia on chromosome 17p. Hum Genet 2007;121:413-420.
- 51 146 Caballero Oteyza A, Battaloglu E, Ocek L, Lindig T, Reichbauer J, Rebelo AP, Gonzalez MA, Zorlu
52 Y, Ozes B, Timmann D, Bender B, Woehlke G, Zuchner S, Schols L, Schule R: Motor protein mutations
53 cause a new form of hereditary spastic paraplegia. Neurology 2014;82:2007-2016.

- 1 147 Dor T, Cinnamon Y, Raymond L, Shaag A, Bouslam N, Bouhouche A, Gausson M, Meyer V, Durr
2 A, Brice A, Benomar A, Stevanin G, Schuelke M, Edvardson S: KIF1C mutations in two families with
3 hereditary spastic paraparesis and cerebellar dysfunction. *J Med Genet* 2014;51:137-142.
- 4 148 Kremer LS, Distelmaier F, Alhaddad B, Hempel M, Iuso A, Kupper C, Muhlhausen C, Kovacs-
5 Nagy R, Satanovskij R, Graf E, Berutti R, Eckstein G, Durbin R, Sauer S, Hoffmann GF, Strom TM, Santer
6 R, Meitinger T, Klopstock T, Prokisch H, Haack TB: Bi-allelic Truncating Mutations in TANGO2 Cause
7 Infancy-Onset Recurrent Metabolic Crises with Encephalocardiomyopathy. *Am J Hum Genet*
8 2016;98:358-362.
- 9 149 Lalani SR, Liu P, Rosenfeld JA, Watkin LB, Chiang T, Leduc MS, Zhu W, Ding Y, Pan S, Vetrini F,
10 Miyake CY, Shinawi M, Gambin T, Eldomery MK, Akdemir ZH, Emrick L, Wilnai Y, Schelley S, Koenig MK,
11 Memon N, Farach LS, Coe BP, Azamian M, Hernandez P, Zapata G, Jhangiani SN, Muzny DM, Lotze T,
12 Clark G, Wilfong A, Northrup H, Adesina A, Bacino CA, Scaglia F, Bonnen PE, Crosson J, Duis J, Maegawa
13 GH, Coman D, Inwood A, McGill J, Boerwinkle E, Graham B, Beaudet A, Eng CM, Hanchard NA, Xia F,
14 Orange JS, Gibbs RA, Lupski JR, Yang Y: Recurrent Muscle Weakness with Rhabdomyolysis, Metabolic
15 Crises, and Cardiac Arrhythmia Due to Bi-allelic TANGO2 Mutations. *Am J Hum Genet* 2016;98:347-
16 357.
- 17 150 Corbett MA, Schwake M, Bahlo M, Dibbens LM, Lin M, Gandolfo LC, Vears DF, O'Sullivan JD,
18 Robertson T, Bayly MA, Gardner AE, Vlaar AM, Korenke GC, Bloem BR, de Coo IF, Verhagen JM,
19 Lehesjoki AE, Gecz J, Berkovic SF: A mutation in the Golgi Qb-SNARE gene GOSR2 causes progressive
20 myoclonus epilepsy with early ataxia. *Am J Hum Genet* 2011;88:657-663.
- 21 151 van Egmond ME, Verschuuren-Bemelmans CC, Nibbeling EA, Elting JW, Sival DA, Brouwer OF,
22 de Vries JJ, Kremer HP, Sinke RJ, Tijssen MA, de Koning TJ: Ramsay Hunt syndrome: clinical
23 characterization of progressive myoclonus ataxia caused by GOSR2 mutation. *Movement disorders :*
24 *official journal of the Movement Disorder Society* 2014;29:139-143.
- 25 152 Kurth I, Pamminger T, Hennings JC, Soehendra D, Huebner AK, Rotthier A, Baets J, Senderek J,
26 Topaloglu H, Farrell SA, Nurnberg G, Nurnberg P, De Jonghe P, Gal A, Kaether C, Timmerman V, Hubner
27 CA: Mutations in FAM134B, encoding a newly identified Golgi protein, cause severe sensory and
28 autonomic neuropathy. *Nat Genet* 2009;41:1179-1181.
- 29 153 Thoenes M, Zimmermann U, Ebermann I, Ptok M, Lewis MA, Thiele H, Morlot S, Hess MM, Gal
30 A, Eisenberger T, Bergmann C, Nurnberg G, Nurnberg P, Steel KP, Knipper M, Bolz HJ: OSBPL2 encodes
31 a protein of inner and outer hair cell stereocilia and is mutated in autosomal dominant hearing loss
32 (DFNA67). *Orphanet journal of rare diseases* 2015;10:15.
- 33 154 Xing G, Yao J, Wu B, Liu T, Wei Q, Liu C, Lu Y, Chen Z, Zheng H, Yang X, Cao X: Identification of
34 OSBPL2 as a novel candidate gene for progressive nonsyndromic hearing loss by whole-exome
35 sequencing. *Genetics in medicine : official journal of the American College of Medical Genetics*
36 2015;17:210-218.
- 37 155 Ammann S, Schulz A, Krageloh-Mann I, Dieckmann NM, Niethammer K, Fuchs S, Eckl KM, Plank
38 R, Werner R, Altmuller J, Thiele H, Nurnberg P, Bank J, Strauss A, von Bernuth H, Zur Stadt U, Grieve S,
39 Griffiths GM, Lehmeberg K, Hennies HC, Ehl S: Mutations in AP3D1 associated with immunodeficiency
40 and seizures define a new type of Hermansky-Pudlak syndrome. *Blood* 2016;127:997-1006.
- 41 156 Soong BW, Morrison PJ: Spinocerebellar ataxias. *Handbook of clinical neurology* 2018;155:143-
42 174.
- 43 157 Edvardson S, Yi JK, Jalas C, Xu R, Webb BD, Snider J, Fedick A, Kleinman E, Treff NR, Mao C,
44 Elpeleg O: Deficiency of the alkaline ceramidase ACER3 manifests in early childhood by progressive
45 leukodystrophy. *J Med Genet* 2016;53:389-396.
- 46 158 Inloes JM, Hsu KL, Dix MM, Viader A, Masuda K, Takei T, Wood MR, Cravatt BF: The hereditary
47 spastic paraplegia-related enzyme DDHD2 is a principal brain triglyceride lipase. *Proc Natl Acad Sci U S*
48 *A* 2014;111:14924-14929.
- 49 159 Schuurs-Hoeijmakers JH, Geraghty MT, Kamsteeg EJ, Ben-Salem S, de Bot ST, Nijhof B, van de
50 V, II, van der Graaf M, Nobau AC, Otte-Holler I, Vermeer S, Smith AC, Humphreys P, Schwartzentruber
51 J, Consortium FC, Ali BR, Al-Yahyaee SA, Tariq S, Pramathan T, Bayoumi R, Kremer HP, van de
52 Warrenburg BP, van den Akker WM, Gilissen C, Veltman JA, Janssen IM, Vulto-van Silfhout AT, van der
53 Velde-Visser S, Lefeber DJ, Diekstra A, Erasmus CE, Willemsen MA, Vissers LE, Lammens M, van

- 1 Bokhoven H, Brunner HG, Wevers RA, Schenck A, Al-Gazali L, de Vries BB, de Brouwer AP: Mutations in
2 DDHD2, encoding an intracellular phospholipase A(1), cause a recessive form of complex hereditary
3 spastic paraplegia. *Am J Hum Genet* 2012;91:1073-1081.
- 4 160 Hansen L, Tawamie H, Murakami Y, Mang Y, ur Rehman S, Buchert R, Schaffer S, Muhammad S,
5 Bak M, Nothen MM, Bennett EP, Maeda Y, Aigner M, Reis A, Kinoshita T, Tommerup N, Baig SM, Abou
6 Jamra R: Hypomorphic mutations in PGAP2, encoding a GPI-anchor-remodeling protein, cause
7 autosomal-recessive intellectual disability. *Am J Hum Genet* 2013;92:575-583.
- 8 161 Howard MF, Murakami Y, Pagnamenta AT, Daumer-Haas C, Fischer B, Hecht J, Keays DA, Knight
9 SJ, Kolsch U, Kruger U, Leiz S, Maeda Y, Mitchell D, Mundlos S, Phillips JA, 3rd, Robinson PN, Kini U,
10 Taylor JC, Horn D, Kinoshita T, Krawitz PM: Mutations in PGAP3 impair GPI-anchor maturation, causing
11 a subtype of hyperphosphatasia with mental retardation. *Am J Hum Genet* 2014;94:278-287.
- 12 162 Krawitz PM, Murakami Y, Riess A, Hietala M, Kruger U, Zhu N, Kinoshita T, Mundlos S, Hecht J,
13 Robinson PN, Horn D: PGAP2 mutations, affecting the GPI-anchor-synthesis pathway, cause
14 hyperphosphatasia with mental retardation syndrome. *Am J Hum Genet* 2013;92:584-589.
- 15 163 Naseer MI, Rasool M, Jan MM, Chaudhary AG, Pushparaj PN, Abuzenadah AM, Al-Qahtani MH:
16 A novel mutation in PGAP2 gene causes developmental delay, intellectual disability, epilepsy and
17 microcephaly in consanguineous Saudi family. *Journal of the neurological sciences* 2016;371:121-125.
- 18 164 Perez Y, Wormser O, Sadaka Y, Birk R, Narkis G, Birk OS: A Rare Variant in PGAP2 Causes
19 Autosomal Recessive Hyperphosphatasia with Mental Retardation Syndrome, with a Mild Phenotype in
20 Heterozygous Carriers. *BioMed research international* 2017;2017:3470234.
- 21 165 Bosch DG, Boonstra FN, Kinoshita T, Jhangiani S, de Ligt J, Cremers FP, Lupski JR, Murakami Y,
22 de Vries BB: Cerebral visual impairment and intellectual disability caused by PGAP1 variants. *Eur J Hum
23 Genet* 2015;23:1689-1693.
- 24 166 Murakami Y, Tawamie H, Maeda Y, Buttner C, Buchert R, Radwan F, Schaffer S, Sticht H, Aigner
25 M, Reis A, Kinoshita T, Jamra RA: Null mutation in PGAP1 impairing Gpi-anchor maturation in patients
26 with intellectual disability and encephalopathy. *PLoS Genet* 2014;10:e1004320.
- 27 167 Schachter H, Jaeken J: Carbohydrate-deficient glycoprotein syndrome type II. *Biochim Biophys
28 Acta* 1999;1455:179-192.
- 29 168 Hansske B, Thiel C, Lubke T, Hasilik M, Honing S, Peters V, Heidemann PH, Hoffmann GF,
30 Berger EG, von Figura K, Korner C: Deficiency of UDP-galactose:N-acetylglucosamine beta-1,4-
31 galactosyltransferase I causes the congenital disorder of glycosylation type II. *J Clin Invest*
32 2002;109:725-733.
- 33 169 Bielas SL, Silhavy JL, Brancati F, Kisseleva MV, Al-Gazali L, Sztriha L, Bayoumi RA, Zaki MS,
34 Abdel-Aleem A, Rosti RO, Kayserili H, Swistun D, Scott LC, Bertini E, Boltshauser E, Fazzi E, Travaglini L,
35 Field SJ, Gayral S, Jacoby M, Schurmans S, Dallapiccola B, Majerus PW, Valente EM, Gleeson JG:
36 Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol
37 signaling to the ciliopathies. *Nat Genet* 2009;41:1032-1036.
- 38 170 Jacoby M, Cox JJ, Gayral S, Hampshire DJ, Ayub M, Blockmans M, Pernot E, Kisseleva MV,
39 Compere P, Schiffmann SN, Gergely F, Riley JH, Perez-Morga D, Woods CG, Schurmans S: INPP5E
40 mutations cause primary cilium signaling defects, ciliary instability and ciliopathies in human and
41 mouse. *Nat Genet* 2009;41:1027-1031.
- 42 171 Bandmann O, Weiss KH, Kaler SG: Wilson's disease and other neurological copper disorders.
43 *The Lancet Neurology* 2015;14:103-113.
- 44 172 Lowe M: Structural organization of the Golgi apparatus. *Curr Opin Cell Biol* 2011;23:85-93.
- 45 173 Wei JH, Seemann J: Unraveling the Golgi ribbon. *Traffic* 2010;11:1391-1400.
- 46 174 Short B, Haas A, Barr FA: Golgins and GTPases, giving identity and structure to the Golgi
47 apparatus. *Biochim Biophys Acta* 2005;1744:383-395.
- 48 175 Gosavi P, Gleeson PA: The Function of the Golgi Ribbon Structure - An Enduring Mystery
49 Unfolds! *BioEssays : news and reviews in molecular, cellular and developmental biology* 2017;39
- 50 176 Ramirez IB, Lowe M: Golgins and GRASPs: holding the Golgi together. *Seminars in cell &
51 developmental biology* 2009;20:770-779.

- 1 177 Opdam FJ, Echard A, Croes HJ, van den Hurk JA, van de Vorstenbosch RA, Ginsel LA, Goud B,
2 Fransen JA: The small GTPase Rab6B, a novel Rab6 subfamily member, is cell-type specifically
3 expressed and localised to the Golgi apparatus. *J Cell Sci* 2000;113 (Pt 15):2725-2735.
- 4 178 Young J, Menetrey J, Goud B: RAB6C is a retrogene that encodes a centrosomal protein
5 involved in cell cycle progression. *Journal of molecular biology* 2010;397:69-88.
- 6 179 Kodani A, Kristensen I, Huang L, Sutterlin C: GM130-dependent control of Cdc42 activity at the
7 Golgi regulates centrosome organization. *Mol Biol Cell* 2009;20:1192-1200.
- 8 180 Kodani A, Sutterlin C: The Golgi protein GM130 regulates centrosome morphology and
9 function. *Mol Biol Cell* 2008;19:745-753.
- 10 181 Preisinger C, Short B, De Corte V, Bruyneel E, Haas A, Kopajtich R, Gettemans J, Barr FA: YSK1 is
11 activated by the Golgi matrix protein GM130 and plays a role in cell migration through its substrate 14-
12 3-3zeta. *The Journal of cell biology* 2004;164:1009-1020.
- 13 182 Rivero S, Cardenas J, Bornens M, Rios RM: Microtubule nucleation at the cis-side of the Golgi
14 apparatus requires AKAP450 and GM130. *EMBO J* 2009;28:1016-1028.
- 15 183 Huang W, She L, Chang XY, Yang RR, Wang L, Ji HB, Jiao JW, Poo MM: Protein kinase LKB1
16 regulates polarized dendrite formation of adult hippocampal newborn neurons. *Proc Natl Acad Sci U S*
17 *A* 2014;111:469-474.
- 18 184 Bisel B, Wang Y, Wei JH, Xiang Y, Tang D, Miron-Mendoza M, Yoshimura S, Nakamura N,
19 Seemann J: ERK regulates Golgi and centrosome orientation towards the leading edge through
20 GRASP65. *The Journal of cell biology* 2008;182:837-843.
- 21 185 Liu S, Storrie B: How Rab proteins determine Golgi structure. *International review of cell and*
22 *molecular biology* 2015;315:1-22.
- 23 186 Sutterlin C, Colanzi A: The Golgi and the centrosome: building a functional partnership. *The*
24 *Journal of cell biology* 2010;188:621-628.
- 25 187 Colanzi A, Corda D: Mitosis controls the Golgi and the Golgi controls mitosis. *Curr Opin Cell Biol*
26 2007;19:386-393.
- 27 188 Colanzi A, Sutterlin C: Signaling at the Golgi during mitosis. *Methods in cell biology*
28 2013;118:383-400.
- 29 189 Corda D, Barretta ML, Cervigni RI, Colanzi A: Golgi complex fragmentation in G2/M transition:
30 An organelle-based cell-cycle checkpoint. *IUBMB life* 2012;64:661-670.
- 31 190 Cervigni RI, Barretta ML, Persico A, Corda D, Colanzi A: The role of Aurora-A kinase in the Golgi-
32 dependent control of mitotic entry. *Bioarchitecture* 2011;1:61-65.
- 33 191 Arai Y, Taverna E: Neural Progenitor Cell Polarity and Cortical Development. *Frontiers in*
34 *cellular neuroscience* 2017;11:384.
- 35 192 Zhou Y, Atkins JB, Rompani SB, Bancescu DL, Petersen PH, Tang H, Zou K, Stewart SB, Zhong W:
36 The mammalian Golgi regulates numb signaling in asymmetric cell division by releasing ACBD3 during
37 mitosis. *Cell* 2007;129:163-178.
- 38 193 Taniguchi M, Yoshida H: TFE3, HSP47, and CREB3 Pathways of the Mammalian Golgi Stress
39 Response. *Cell structure and function* 2017;42:27-36.
- 40 194 Ge L, Wilz L, Schekman R: Biogenesis of autophagosomal precursors for LC3 lipidation from the
41 ER-Golgi intermediate compartment. *Autophagy* 2015;11:2372-2374.
- 42 195 Lamb CA, Yoshimori T, Tooze SA: The autophagosome: origins unknown, biogenesis complex.
43 *Nature reviews Molecular cell biology* 2013;14:759-774.
- 44 196 Fernandez-Fernandez MR, Ruiz-Garcia D, Martin-Solana E, Chichon FJ, Carrascosa JL, Fernandez
45 JJ: 3D electron tomography of brain tissue unveils distinct Golgi structures that sequester cytoplasmic
46 contents in neurons. *J Cell Sci* 2017;130:83-89.
- 47 197 Geng J, Klionsky DJ: The Golgi as a potential membrane source for autophagy. *Autophagy*
48 2010;6:950-951.
- 49 198 Itoh T, Fujita N, Kanno E, Yamamoto A, Yoshimori T, Fukuda M: Golgi-resident small GTPase
50 Rab33B interacts with Atg16L and modulates autophagosome formation. *Mol Biol Cell* 2008;19:2916-
51 2925.

- 1 199 Longatti A, Lamb CA, Razi M, Yoshimura S, Barr FA, Tooze SA: TBC1D14 regulates
2 autophagosome formation via Rab11- and ULK1-positive recycling endosomes. *The Journal of cell*
3 *biology* 2012;197:659-675.
- 4 200 Oda S, Nozawa T, Nozawa-Minowa A, Tanaka M, Aikawa C, Harada H, Nakagawa I: Golgi-
5 Resident GTPase Rab30 Promotes the Biogenesis of Pathogen-Containing Autophagosomes. *PLoS One*
6 2016;11:e0147061.
- 7 201 Wen H, Zhan L, Chen S, Long L, Xu E: Rab7 may be a novel therapeutic target for neurologic
8 diseases as a key regulator in autophagy. *J Neurosci Res* 2017
- 9 202 Reggiori F, Ungermann C: Autophagosome Maturation and Fusion. *Journal of molecular*
10 *biology* 2017;429:486-496.
- 11 203 He C, Levine B: The Beclin 1 interactome. *Curr Opin Cell Biol* 2010;22:140-149.
- 12 204 He S, Ni D, Ma B, Lee JH, Zhang T, Ghozalli I, Pirooz SD, Zhao Z, Bharatham N, Li B, Oh S, Lee
13 WH, Takahashi Y, Wang HG, Minassian A, Feng P, Deretic V, Pepperkok R, Tagaya M, Yoon HS, Liang C:
14 PtdIns(3)P-bound UVRAG coordinates Golgi-ER retrograde and Atg9 transport by differential
15 interactions with the ER tether and the beclin 1 complex. *Nat Cell Biol* 2013;15:1206-1219.
- 16 205 Feng Y, Klionsky DJ: Autophagic membrane delivery through ATG9. *Cell research* 2017;27:161-
17 162.
- 18 206 Young AR, Chan EY, Hu XW, Kochl R, Crawshaw SG, High S, Hailey DW, Lippincott-Schwartz J,
19 Tooze SA: Starvation and ULK1-dependent cycling of mammalian Atg9 between the TGN and
20 endosomes. *J Cell Sci* 2006;119:3888-3900.
- 21 207 Guo Y, Chang C, Huang R, Liu B, Bao L, Liu W: AP1 is essential for generation of
22 autophagosomes from the trans-Golgi network. *J Cell Sci* 2012;125:1706-1715.
- 23 208 Mattera R, Park SY, De Pace R, Guardia CM, Bonifacino JS: AP-4 mediates export of ATG9A
24 from the trans-Golgi network to promote autophagosome formation. *Proc Natl Acad Sci U S A*
25 2017;114:E10697-E10706.
- 26 209 Ayala I, Colanzi A: Alterations of Golgi organization in Alzheimer's disease: A cause or a
27 consequence? *Tissue & cell* 2017;49:133-140.
- 28 210 Gonatas NK, Stieber A, Gonatas JO: Fragmentation of the Golgi apparatus in
29 neurodegenerative diseases and cell death. *Journal of the neurological sciences* 2006;246:21-30.
- 30 211 Sundaramoorthy V, Sultana JM, Atkin JD: Golgi fragmentation in amyotrophic lateral sclerosis,
31 an overview of possible triggers and consequences. *Frontiers in neuroscience* 2015;9:400.
- 32 212 Hicks SW, Machamer CE: Golgi structure in stress sensing and apoptosis. *Biochim Biophys Acta*
33 2005;1744:406-414.
- 34 213 Hicks SW, Machamer CE: The NH2-terminal domain of Golgin-160 contains both Golgi and
35 nuclear targeting information. *J Biol Chem* 2002;277:35833-35839.
- 36 214 Mukherjee S, Shields D: Nuclear import is required for the pro-apoptotic function of the Golgi
37 protein p115. *J Biol Chem* 2009;284:1709-1717.
- 38 215 Herrup K: Post-mitotic role of the cell cycle machinery. *Curr Opin Cell Biol* 2013;25:711-716.

39

40

TABLE 1. Golgipathies associated with Postnatal-Onset Microcephaly

Disease/Syndrome	# MIM	Mode of Inheritance	GA protein	Major neurological signs
Dyggve-Melchior-Clausen syndrome (DMC)	223800	AR	DYMECLIN	POM, ID, thin corpus callosum
Warburg-Micro syndrome (WARBM1-4)	600118	AR	RAB3GAP1	POM, ID, progressive limb spasticity, peripheral axonal neuropathy, visual impairment, thin corpus callosum
	614225	AR	RAB3GAP2	
	614222	AR	RAB18	
	615663	AR	TBC1D20	
Neurodevelopmental Disorder with Microcephaly, Epilepsy, Brain Atrophy (NEDMEBA)	617862	AR	TRAPPC6B	POM, ID, hypotonia, hand tremors, seizures
Autosomal Recessive Mental Retardation 13 (MRT13)	613192	AR	TRAPPC9	POM, ID, thin corpus callosum
Progressive Childhood Encephalopathy (PEBAS)	617669	AR	TRAPPC12	POM or PM, truncal hypotonia with appendicular spasticity, visual impairment, partial agenesis of the corpus callosum
Autosomal Recessive Mental Retardation 61 (MRT61)	617773	AR	IPORIN	POM, ID, thin corpus callosum
Autosomal Dominant Mental Retardation 34 (MRD34)	616351	AD	COL4A3BP	POM, ID, visual impairment, seizures
Cohen syndrome (COH)	216550	AR	VPS13B	POM, ID, visual impairment, short and thick corpus callosum
Pontocerebellar Hypoplasia Type 2E (PCH2E)	615851	AR	VPS53	POM, pontocerebellar hypoplasia, progressive spasticity, seizures, thin corpus callosum
Pontocerebellar Hypoplasia Type 11 (PCH11)	617695	AR	TBC1D23	POM, ID, pontocerebellar hypoplasia, thin corpus callosum
Autosomal Recessive Periventricular Heterotopia with Microcephaly (ARPHM)	608097	AR	BIG2	POM, ID, periventricular heterotopia, seizures, thin corpus callosum
POM-associated Congenital Disorders of Glycosylation (CDG types 2C, 2E, 2F, 2G, 2H, 2I, 2J, 2K, 2M, 2Q, SHNS, AMRS)	611209	AR	COG1	POM, ID, multiple and variable neurological manifestations
	617395	AR	COG2	
	613489	AR	COG4	
	613612	AR	COG5	
	615328	AR	COG6	
	608779	AR	COG7	
	611182	AR	COG8	
	603585	AR	SLC35A1	
	300896	XLD	SLC35A2	
	615553	AR	SLC35A3	
	266265	AR	SLC35C1	
614727	AR	TMEM165		
Mental Retardation, Enteropathy, Deafness, Peripheral Neuropathy, Ichthyosis, Keratoderma (MEDNIK)	609313	AR	AP1S1	POM, ID, peripheral neuropathy
Takenouchi-Kosaki syndrome (TKS)	616737	AD	CDC42	POM or PM, ID, seizures, visual impairments, thin corpus callosum
Neuromuscular syndrome with Microcephaly	602580*	AR	GM130	POM, central hypotonia, thin corpus callosum
Novel Pontocerebellar Hypoplasia	NA	AR	VPS51	POM, ID, pontocerebellar hypoplasia, visual impairment, thin corpus callosum

AR=Autosomal Recessive, AD=Autosomal Dominant, XLD=X-linked Dominant

*OMIM reference corresponds to the gene instead of the disease.

TABLE 2.

Golgiopathies associated with Primary or Unknown-onset Microcephaly or Macrocephaly

Disease/Syndrome	# MIM	Mode of Inheritance	GA protein	Major neurological signs
Autosomal Recessive Primary Microcephaly type 2 (MCPH2)	604317	AR	WDR62	PM, ID, seizures
Autosomal Recessive Primary Microcephaly type 3 (MCPH3)	604804	AR	CDK5RAP2	PM, ID
Limb Girdle Muscular Dystrophy (LGMDR18)	615356	AR	TRAPPC11	Microcephaly of unknown onset, ID, limb spasticity, seizures, ataxia, visual impairments
Autosomal Dominant Microcephalic dwarfism with micrognathia (SRMMD)	617164	AD	COPD	PM, ID, mild cerebellar atrophy, visual impairments, thin corpus callosum
Autosomal Recessive Primary Microcephaly type 19 (MCPH19)	617800	AR	COPB2	PM, ID, spasticity, visual impairments, thin corpus callosum
Progressive Encephalopathy with Edema, Hypsarrhythmia and Optic Atrophy-like syndrome (PEHOL)	617507	AR	GIRDIN	PM, ID, severe encephalopathy, seizures, hypotonia, peripheral hypertonia with spasticity, visual impairments, thin corpus callosum
AP4-deficiency Syndrome	613744 612936 614066 614067	AR AR AR AR	AP4E1 AP4M1 AP4B1 AP4S1	PM, ID Spastic paraplegia Neonatal hypotonia
Hermansky-Pudlak syndrome (HPS2)	608233	AR	AP3B1	Microcephaly of unknown onset, ID
Christianson Syndrome (MRXSCH)	300243	XLD	SLC9A6	PM or Microcephaly of unknown onset, ID, seizures, visual impairments
Pettigrew syndrome (PGS)	304340	XLR	AP1S2	Microcephaly of unknown onset, ID, seizures, Dandy-Walker malformation
Early Infantile Epileptic Encephalopathy (EIEE49)	617281	AR	DENND5A	Microcephaly of unknown onset, ID, spastic tetraplegia, seizures, visual impairment, corpus callosum dysgenesis
X-linked form of ID (MRX72)	300271	XLR	RAB39B	Macrocephaly ID
Waisman syndrome (WSMN)	311510	XLR	RAB39B	Early onset Parkinsonism
Macrocephaly, Dysmorphic Facies and Psychomotor Retardation (MDFPMR)	617011	AR	HERC1	Macrocephaly, ID, seizures, hypotonia, ataxia
Polyhydramnios, Megalencephaly and Symptomatic Epilepsy (PMSE)	611087	AR	STRADA	Macrocephaly, ID, seizures, hypotonia
Autosomal Dominant Mental Retardation (MRD48)	617751	AD	RAC1	Microcephaly of unknown onset or macrocephaly, ID, seizures, thin corpus callosum

AR=Autosomal Recessive, AD=Autosomal Dominant, XLD=X-linked Dominant, XLR=X-linked Recessive

TABLE 3. Neurodevelopmental Golgipathies without Microcephaly

Disease/Syndrome	# MIM	Mode of Inheritance	GA protein	Major neurological signs
Non-syndromic form of ID (MRX41)	300849	XLD	GDI1	ID of variable severity
Periventricular Nodular Heterotopia (PVNH1)	300049	XLD	FLNA	ID in males Epilepsy
Schuurs-Hoeijmakers syndrome (SHMS)	615009	AD	PACS1	ID with remarkable similarity in facial features
Autosomal Recessive Spinocerebellar Ataxia (SCAR21)	616719	AR	SCYL1	ID, Cerebellar atrophy; peripheral neuropathy
Autosomal Dominant Spinal Muscular Atrophy (SMALED2)	615290	AD	BICAUDAL	Spasticity
Autosomal Recessive spastic Ataxia (SPAX2)	611302	AR	KIF1C	Cerebellar ataxia Atrophy of the corpus callosum
Metabolic Encephalomyopathic Crises, Recurrent with Rhabdomyolysis, Cardiac Arrhythmias and Neurodegeneration (MECRCN)	616878	AR	TANGO2	Muscle weakness, ataxia, seizures
Progressive Myoclonic Epilepsy (EPM6)	614018	AR	GOSR2	Progressive ataxia Seizures
Neuropathy Hereditary Sensory and Autonomic type IIB (HSAN2B)	613115	AR	FAM134B	Childhood onset autonomic neuropathy, sensory deficits, loss of myelinating fibers
Deafness Autosomal Dominant 67 (DFNA67)	616340	AD	OSBPL2	Sensorineural hearing loss
Hermansky-Pudlak syndrome (HSP10)	617050	AR	AP3D1	Epilepsy Neurodevelopmental delay Intractable myoclonic seizures

AR=Autosomal Recessive, AD=Autosomal Dominant, XLD=X-linked Dominant

1 **Legend to Figure 1: Temporal relationship between major stages of central nervous**
2 **system development and various physiological functions of the Golgi apparatus**

3 Schematic representation summarizing some of the physiological functions of the Golgi
4 apparatus (GA) proteins (upper section) and major developmental processes of the central
5 nervous system in which these proteins are involved during embryonic/fetal and postnatal life
6 (lower section). Proteins involved in the maintenance of GA structure, integrity and position
7 are required throughout life, as are those involved in the biosynthesis and modification of
8 certain lipids and most proteins. However, the need for other GA functions increases
9 periodically, and proteins involved in these functions may not play a role throughout life or
10 may switch to other roles depending on the stage of the lifespan. For example, during
11 neurogenesis and gliogenesis, when mitotic activity predominates, GA proteins involved in cell
12 cycle regulation (yellow) would be expected to play a major role, and defects in these proteins
13 would have maximum impact and lead to disorders reflecting a lack of neurons and glia. At
14 later stages, other functions predominate, such as cellular polarity and microtubule organization
15 (orange; particularly important for migration and morphogenesis, including the establishment
16 and maturation of the axon and dendritic arbor), apoptosis (violet; crucial for the programmed
17 death of the large excess of neurons produced), autophagy (pink; necessary to remodel the cell
18 but also important in maintenance and repair throughout the lifespan, when it is involved in
19 neurodegenerative processes) and secretory and membrane trafficking (blue; essential for the
20 huge expansion of the cell membrane and secretory activity during synaptogenesis in neurons,
21 branching of astrocytes and myelination by oligodendrocytes, but also necessary for neuronal
22 and glial function throughout the lifespan). NB: the timeline of some of the processes
23 described, for example neurogenesis and myelination, is still subject to debate; some processes
24 involve two or more GA functions simultaneously.

25

